# Estimating the cognitive effects of statins from observational data using the survival-incorporated median: a summary measure for clinical outcomes in the presence of death 

Qingyan Xiang 1, Paola Sebastiani 2, Thomas Perls 3, Stacy L. Andersen 3, Svetlana Ukraintseva 4, Mikael Thinggaard 5, and Judith J. Lok $6^{*}$<br>1 Department of Biostatistics, Boston University<br>2 Tufts Medical Center<br>3 Department of Medicine, Boston University<br>4 Social Science Research Institute, Duke University<br>5 Department of Public Health, University of Southern Denmark 6 Department of Mathematics and Statistics, Boston University

July 2, 2024


#### Abstract

The issue of "truncation by death" commonly arises in clinical research: subjects may die before their follow-up assessment, resulting in undefined clinical outcomes. This article addresses truncation by death by analyzing the Long Life Family Study (LLFS), a multicenter observational study involving over 4000 older adults with familial longevity. We are interested in the cognitive effects of statins in LLFS participants, as the impact of statins on cognition remains unclear despite their widespread use. In this application, rather than treating death as a mechanism through which clinical outcomes are missing, we advocate treating death as part of the outcome measure. We focus on the survival-incorporated median - the median of a composite outcome combining death and cognitive scores-to summarize the effect of statins. We propose an estimator for the survival-incorporated median from observational


[^0]data, applicable in both point-treatment settings and time-varying treatment settings. Simulations demonstrate the survival-incorporated median as a simple and useful summary measure. We apply this method to estimate the effect of statins on the change in cognitive function (measured by the Digit Symbol Substitution Test), incorporating death. Our results indicate no significant difference in cognitive decline between participants with a similar age distribution on and off statins from baseline. Through this application, we aim to not only contribute to this clinical question but also offer insights into analyzing clinical outcomes in the presence of death.

Keywords: Causal inference; Truncation by death; Survival; Observational data; Cognitive function; Longevity

## 1 Introduction

### 1.1 Motivation and objectives

The issue of "truncation by death" presents a common challenge in clinical research: subjects may die before the follow-up assessment, resulting in undefined clinical outcomes. This issue is particularly prevalent in longitudinal studies of older adults, where death is common yet related to many clinical outcomes such as cognitive and physical function. In addition, death can gradually alter the composition of a study population Murphy et al., 2011]. Therefore, simply treating the death as censoring or missing may lead to biased estimates and misleading conclusions [Colantuoni et al., 2018.

This article focuses on the Long Life Family Study (LLFS), an international multicenter observational study involving more than 4000 older adults with exceptional longevity Wojczynski et al., 2022, Xiang et al., 2023a. Since the study includes older adults who are at risk of death, analyzing the LLFS requires careful consideration of the issue of truncation by death.

Our clinical question of interest is the effect of statins on the change in cognitive function of LLFS participants. Statins, widely prescribed for lowering cholesterol and cardiovascular conditions, are used by nearly $30 \%$ of adults 40 years and older in the United States Schultz et al., 2018. Despite the widespread use of statins, their impact on cognitive function remains a debate Ott et al., 2015, Schultz et al., 2018, Adhikari et al., 2021, Ying et al., 2021, Olmastroni et al., 2022. In the literature, some studies indicate a potential risk of cognitive impairment in specific patient groups Muldoon et al., 2000, Alsehli et al., 2020, while other studies suggest no significant risk or even a protective effect on cognitive function [Benito-León et al., 2010, Petek et al., 2023]. The complexity of the relationship
between statins and cognitive function necessitates further research.
Many of the aforementioned studies address the missing values inadequately or even overlook the aspect of death. For example, Alsehli et al. 2020 "excluded all data sets containing missing values" and perform a survivors-only analysis. This survivors-only analysis is known to be affected by the "healthy-survivors" effect and is subject to bias Rothman et al., 2008. Petek et al. 2023 mention the considerable number of patients who dropped out, and they applied Inverse Probability of Censoring Weighting (IPCW) [Hernán et al., 2000] to handle death and missingness together. However, death leads to undefined outcomes rather than missing outcomes, so it is inappropriate to treat death the same as missingness; IPCW transfers the weight of dead patients to those alive. These two approaches, survivors-only analyses and IPCW, are common in dealing with undefined outcomes due to death but may lead to biased conclusions.

The objectives of this study are twofold: (i) to estimate the effect of statins on the change in cognitive function of participants from the observational LLFS, and (ii) to properly address the issue of truncation by death in analyzing the data. Through this application, we aim to not only contribute to this clinical question regarding statins but also offer insights into analyzing clinical studies in the presence of death.

### 1.2 Research method

To address the issue of truncation by death, we advocate summarizing the clinical benefit of treatment by combining death and the clinical outcome into a ranked composite outcome $\tilde{Y}$ Lachin, 1999, Joshua Chen et al., 2005, Lok et al., 2010, Wang et al., 2017. Because the ranked outcomes are a composition of two types of outcomes (death and clinical outcomes) with different scales, it is inappropriate to draw inference using the mean of the composite
outcome. Instead, we compare the distribution or quantiles of the composite outcome $\tilde{Y}$ to assess the clinical benefit of treatment regarding both survival and clinical outcomes. Since the probability of death is less than $50 \%$ in the LLFS participants included in this analysis, we propose using the median of the composite outcome - the survival-incorporated median - in the analysis Lok et al., 2010, Xiang et al., 2023b. One can consider other quantiles, for example, the survival-incorporated 75 th quantile or 90th quantile, when the probability of death is greater than $50 \%$.

To estimate the survival-incorporated median from observational data in the presence of death, we propose a weighted quantile estimator based on Inverse Probability of Treatment Weighting (IPTW) Robins, 1986, Robins et al., 2000, Hernán et al., 2000. IPTW allows weighting all outcomes, including death, to estimate the marginal quantiles of the potential outcomes $\tilde{Y}^{(a)}$ under the treatment of interest $a$. We show that the proposed estimator for the survival-incorporated quantile works well for point treatments setting with $a=0$ and $a=1$. We also show that, with carefully constructed weights, the estimator can be readily extended to the time-varying treatment settings, which are common in studies with long-term follow-up with subjects at risk of death such as the LLFS.

Besides truncation by death, the LLFS data present another challenge: missing data for various reasons. In this application, we use Inverse Probability of Censoring Weighting (IPCW) to account for missing data.

In the causal inference literature, most studies focus on population means of the potential outcomes. However, inference on quantiles Hogan and Lee, 2004, Firpo, 2007, Zhang et al. 2012, Sherwood et al. 2013 can be especially useful for the important problem of truncation by death. Hogan and Lee 2004 studied the marginal structural quantile regression model and showed that their quantile estimator solves an unbiased estimating equation.

However, due to the non-smooth nature of the quantile estimator and the complexity of nuisance parameters in the propensity score, consistency does not simply follow from an unbiased estimating equation. In this article, we prove both consistency and asymptotic normality for the proposed quantile estimator.

This paper is structured as follows. Section 2 introduces the setting, the definition, and the assumptions for estimation of the survival-incorporated median in the LLFS. Section 3 describes the IPTW estimators of the survival-incorporated quantiles in both pointtreatment settings and time-varying settings. Section 4 applies the survival-incorporated median to study the change in cognitive function of participants in the Long Life Family Study. Section 5 shows statistical properties of the proposed estimators. Section 6 presents simulation studies to investigate the performance of the proposed estimators. A discussion concludes the article in Section 7.

## 2 Setting, definition, and assumptions

### 2.1 Setting of the Long Life Family Study (LLFS)

This article uses the following notation. The study includes $N$ participants with a baseline assessment $(k=0)$, and $k=1, \ldots, K+1$ subsequent follow-up visits. For simplicity, we omit the individual participant index $i(i=1, \ldots, N) . D_{k}$ is the indicator variable of the survival status at time $k$, with $D_{k}=1$ if the participant is dead and $D_{k}=0$ if the participant is alive at time $k . Y$ is the clinical outcome that is measured at time $K+1$, the end of the study, if $D_{(K+1) i}=0$, and $\tilde{Y}$ is the composite outcome that combines $Y$ and death. $L_{k}$ is a vector of covariates representing measured risk factors at time $k, k=0, \ldots, K . A_{k}$ is the indicator variable of the (statin) treatment at time $k$, so $A_{k}=1$ if the participant is on
statins at time $k$ and $A_{k}=0$ if not. At time $k$, in those alive ( $D_{k}=0$ ), a treatment decision $A_{k}$ is made after measuring $L_{k} . \bar{L}_{k}=\left(L_{0}, L_{1}, \ldots, L_{k}\right)$ is the covariate history from baseline to the $k$ th visit, and similarly $\bar{A}_{k}=\left(A_{0}, A_{1}, \ldots, A_{k}\right) . Y^{\left(\bar{a}_{K}\right)}$ is the potential outcome had the participant received treatment regimen $\bar{a}_{K}=\left(a_{0}, a_{1}, \ldots, a_{K}\right)$. The observed data at time $k$ consist of $\left(D_{k}, L_{k}, A_{k}\right), k=0, \ldots, K$. At the last follow-up time $K+1$, we observe $D_{K+1}$ and $Y\left(\right.$ if $\left.D_{K+1}=0\right)$. If a participant $i$ died between the $(m-1)$ th visit and the $m$ th visit, $m=1,2, \ldots, K+1$, then $\left(L_{k}, A_{k}, Y\right)$ for this participant becomes undefined for $k>=m$. The full data are $\left(\bar{L}_{K i}, \bar{A}_{K i}, \bar{D}_{(K+1) i}, \tilde{Y}_{i}\right)$ for participants $i=1, \ldots, N$.

In the LLFS, the cognitive function of participants is assessed at two in person assessments 8 years apart by the Digit Symbol Substitution Test (DSST) Wechsler, 1981. Over the 8 years of follow-up, statin use is measured at baseline, at year 3 , and at year 6 . Thus, the study timeline is: $k=0$ (baseline), $k=1$ (year 3), $k=2$ (year 6), and $k=3$ (year 8). A participant may die in three time intervals: $(0,3],(3,6]$, and $(6,8]$. In the LLFS, the confounders are only measured at baseline, and the vector of baseline confounders $L_{0}$ includes: age at baseline, gender, education, smoking, total cholesterol level, low-density lipoproteins, high-density lipoproteins, and adjusted Framingham risk score (see Appendix Section B.3). The full data include the participants' baseline confounders $L_{0}$, treatment history $\bar{A}_{2}$, death status $D_{k}, k=1,2,3$, and DSST scores $Y$.

We focus on two sub-populations of participants who had a baseline DSST assessment: (1) 1750 participants with age between 55 and $69(55.0<=$ age $<70.0)$ and (2) 664 participants with age between 70 and $84(70.0<=$ age $<85.0)$. Table 1 shows the baseline characteristics of participants in the two age-based sub-populations. Table 2 shows the number of participants on and off statins at baseline and the crude percentage of participants who died.


Table 1: Baseline characteristics of LLFS participants; N, number; IQR, interquartile range; HDL, high-density lipoprotein; LDL, low-density lipoprotein; mg/dL, milligrams per deciliter; $A_{0}=0$, participants off statins at baseline; $A_{0}=1$, participants on statins at baseline.

|  |  | \#Participants | Crude \% of participants who died |
| :---: | :---: | :---: | :---: |
|  | $A_{0}=0$ | 1359 | $4.1 \%$ |
| age 55-69 |  |  |  |
|  | $A_{0}=1$ | 391 | $4.6 \%$ |
|  | $A_{0}=0$ | 414 | $17.6 \%$ |
| age 70-84 | $A_{0}=1$ | 250 | $19.2 \%$ |

Table 2: Death status of the LLFS participants in our analysis. $A_{0}=0$ : participants off statins at baseline. $A_{0}=1$ : participants on statins at baseline. The crude probability of death is calculated by the number of deaths divided by the number of participants in each group.

### 2.2 Definition of the survival-incorporated median

The survival-incorporated median is a summary measure of the ranked composite outcome that combines death and a clinical outcome [Lok et al., 2010, Xiang et al., 2023b]. In this application, since the probability of death is less than $50 \%$ during the 8 -year follow-up, the survival-incorporated median is defined as:

Definition 1 (survival-incorporated median) The threshold such that 50\% of the target LLFS participants is alive with a DSST score higher than that threshold, and $50 \%$ either died or has a DSST score lower than that threshold.

To estimate the survival-incorporated median, all outcomes need to be ranked and combined together into a composite outcome $\tilde{Y}$. In the LLFS, the DSST scores have a range of $[0,93]$, with higher scores suggesting better cognitive function. Since min $Y=0$,
we could assign participants who die any value less than 0 to form the ranked composite outcome.

Mathematically, for the composite outcome $\tilde{Y}^{(\bar{a})}$ under treatment regimen $\bar{a}$ with distribution function $F_{\tilde{Y}(\bar{a})}(y)=P\left(Y^{(\bar{a})} \leq y\right)$, the survival-incorporated median can be defined as

$$
q_{0.5}^{(\bar{a})}=F_{\left.\tilde{Y}^{(\bar{a}}\right)}^{-1}(0.5)=\inf \left\{y: F_{\left.\tilde{Y}^{(\bar{a}}\right)}(y) \geq 0.5\right\}
$$

More generally, the $\tau$ th survival-incorporated quantile is defined as

$$
q_{\tau}^{(\bar{a})}=F_{\tilde{Y}^{( }(\bar{a})}^{-1}(\tau)=\inf \left\{y: F_{\tilde{Y}^{(\bar{a})}}(y) \geq \tau\right\},
$$

for example, the survival-incorporated 75 th quantile $q_{0.75}^{(\bar{a})}$.
For outcomes undefined due to death, the assignment $\tilde{Y}$ is conceptually different from imputing missing values. Imputing missing values, which typically depends on the missing data mechanism, aims to replace a missing value with an estimated value. However, the death of a participant is fully observed, and if a participant died, the participant's clinical outcome is not missing but rather undefined. Therefore, considering death a worse state than being alive, we assign participants who die any value less than the worst clinical outcome. The value of the assigned clinical outcome, which has the lowest ranking in the ranked outcomes, is irrelevant to the value of the survival-incorporated median if the probability of death is less than $50 \%$. Such assignment for undefined outcomes facilitates the computation of the survival-incorporated median or other survival-incorporated quantiles.

### 2.3 Assumptions

Estimating the survival-incorporated quantile from observational data relies on the following identifying assumptions:

Assumption 1 (No Unmeasured Confounding) For all k, $A_{k} \Perp\left(\bar{L}_{k+1}^{\left(\bar{a}_{k}\right)}, \tilde{Y}^{\left(\bar{a}_{K}\right)}\right) \mid \bar{A}_{k-1}=$ $\bar{a}_{k-1}, \bar{L}_{k}=\bar{l}_{k}$.

Assumption 2 (Consistency) For all $k$, if $\bar{A}_{K}=\bar{a}_{K}, \tilde{Y}^{\left(\bar{a}_{K}\right)}=Y$, and if $\bar{A}_{k-1}=\bar{a}_{k-1}$, $\bar{L}_{k}^{\left(\bar{a}_{k-1}\right)}=\bar{L}_{k}$.

Assumption 3 (Positivity) For some $\varepsilon>0, \varepsilon<P\left(A_{k}=a_{k} \mid \bar{A}_{k-1}=\bar{a}_{k-1}, \bar{L}_{k}=\bar{l}_{k}\right)<$ $1-\varepsilon$ for all $\left(\bar{a}_{k}, \bar{l}_{k}\right)$.

Assumptions 1, 2, and 3 are commonly seen in the causal inference literature for the identification and estimation of causal parameters from observational data Hernan and Robins, 2020. No Unmeasured Confounding Assumption 1 requires that all confounders that could influence both the treatment and future potential outcomes are measured and accounted for. In the LLFS, all relevant covariates were only measured at baseline, and we include the covariates listed in Table 1 as confounders because of their potential associations with both cognition and statin treatment. Consistency Assumption 2 requires that the potential outcome for a participant under the treatment they actually received is consistent with their observed outcome. In the LLFS, the status of on/off statins is well-recorded at the follow-up visits to ensure that the observed DSST scores reflect the effect of statins. Positivity Assumption 3 requires that participants with any characteristics, should have some chance of taking statins and of not taking statins.

In addition to the above assumptions, the following assumption is also needed to identify the survival-incorporated quantile:

Assumption 4 (Uniqueness of quantile $\tau$ ) The outcome $\tilde{Y}^{\left(\bar{a}_{K}\right)}$ takes values in $\mathbb{R}$. For all $\bar{a}_{K}$ the $\tau$ th quantile of interest $q_{\tau}^{\left(\bar{a}_{K}\right)}$ satisfies $P\left(\tilde{Y}^{\left(\bar{a}_{K}\right)} \leq q_{\tau}^{\left(\bar{a}_{K}\right)}-\delta\right)<P\left(\tilde{Y}^{\left(\bar{a}_{K}\right)} \leq q_{\tau}^{\left(\bar{a}_{K}\right)}\right)<$ $P\left(\tilde{Y}^{\left(\bar{a}_{K}\right)} \leq q_{\tau}^{\left(\bar{a}_{K}\right)}+\delta\right)$ for all $\delta>0$.

## 3 Estimation of the survival-incorporated median from observational data

### 3.1 Point-treatment settings

We first describe the IPTW estimator of the survival-incorporated median from observational data with a binary treatment $A=0$ or $A=1$ - a "point-treatment" setting. Figure 1 (a) depicts the Directed Acyclic Graph (DAG) for this setting. $L$ is a vector of baseline covariates. After receiving $A=0$ or $A=1$, participants may die before the follow-up assessment $(D=1)$, or may survive with their clinical outcome $Y$ measured.


Figure 1: DAG for (a) a point-treatment setting and (b) a time-varying treatment setting with two post-baseline assessments.

To estimate the survival-incorporated median from observational data, we use IPTW. First, as in Section 2.2, we assign those who die $(D=1)$ a value less than the lowest possible value of $Y$. Next, since the treatment was not randomized, we weight each outcome by the inverse of the participant's probability of receiving their observed treatment $a$ conditional on the baseline covariates $L$, i.e., the inverse of the propensity score, $w_{a}=\mathbb{1}_{A=a} / p(A=$ $a \mid L)$. In observational studies, propensity scores are typically not known. We estimate the
propensity scores $\hat{p}(A=a \mid L)$ assuming that a model for the probability of the treatment is correctly specified, for example, a logistic regression model.

Combining the weights with the quantile estimation procedure proposed by Koenker and Bassett 1978, the IPTW estimator for the survival-incorporated $\tau$ th quantile under treatment $a$ is $\hat{q}_{\tau}^{(a)}$, is:

$$
\begin{equation*}
\hat{q}_{\tau}^{(a)}=\underset{q}{\arg \min } \frac{1}{N} \sum_{i=1}^{N} \hat{w}_{a} \cdot \rho_{\tau}(\tilde{Y}-q) . \tag{1}
\end{equation*}
$$

where $\rho_{\tau}(x)=x\left(\tau-\mathbb{1}_{x \leq 0}\right)$ is the quantile loss function evaluated at $x$ (Koenker 2005), and $w_{a, i}$ is the weight under treatment $a, a=0$ or 1 :

$$
w_{0}=\frac{\mathbb{1}_{A=0}}{P(A=0 \mid L)}, w_{1}=\frac{\mathbb{1}_{A=1}}{P(A=1 \mid L)} .
$$

In addition, estimating equations for $q_{\tau}^{(a)}$ can be expressed as follows:

$$
\begin{equation*}
\Psi_{N}(q)=\frac{1}{N} \sum_{i=1}^{N} \frac{\mathbb{1}_{A=a}}{P(A=a \mid L)}\left(\mathbb{1}_{\tilde{Y} \leq q}-\tau\right) . \tag{2}
\end{equation*}
$$

It is also the gradient function of the objective function in equation (1).

### 3.2 Time-varying settings

Figure 1 (b) depicts the DAG of a time-varying setting with two post-baseline assessments $(K+1=2)$. In general, consider a study with $K+1$ follow-up assessments with participants at risk of death in each time interval. The choice of IPTW weights $\hat{w}_{\bar{a}}$ needs to account for death, which may occur in each period between each visits. The IPTW weight of equation (1) is modified as follows:

$$
\hat{w}_{\bar{a}}= \begin{cases}\frac{\mathbb{1}_{\bar{A}_{K}=\bar{a}_{K}}}{} \quad \text { if } D_{(K+1)}=0, \text { i.e., } \\ \prod_{k=0}^{K} \hat{P}^{\prime}\left(A_{k} \mid \bar{A}_{k-1}, \bar{L}_{k}\right) \\ & \text { a participant survives throughout } \\ \frac{\mathbb{1}_{\bar{A}_{m-1}=\bar{a}_{m-1}}^{m-1}}{\prod_{k=0}^{m} \hat{P}^{\left(A_{k} \mid \bar{A}_{k-1}, \bar{L}_{k}\right)}} & (m-1) \text { th visit and } m \text { th visit. }\end{cases}
$$

IPTW creates a pseudo population where the effects on treatment of the baseline and time-varying confounders are removed Hernan and Robins, 2020]. When a participant $i$ dies between the $(m-1)$ th visit and the $m$ th visit, their clinical outcome and covariates then become undefined starting from time $m$. Such participant's undefined covariates from time $m$ onwards are irrelevant. Hence, the denominator of such a subject's weight is the subject's probability of receiving the treatment history that they received, conditional on their covariate history before the time they die.

## 4 Application: cognitive change in older adults on and off statins

### 4.1 Estimation

We apply our method to estimate the survival-incorporated cognitive change in LLFS participants on and off statins. This application has three main challenges: (1) some DSST scores are undefined due to death, (2) the LLFS is an observational study, and (3) some DSST scores are missing. In this application, we address (1) using the survivalincorporated median, (2) using Inverse Probability of Treatment Weighting (IPTW), and (3) using Inverse Probability of Censoring Weighting (IPCW).

The LLFS does not collect treatment information before baseline. Figure 2 shows the
distributions of total cholesterol in those off statins $\left(A_{0}=0\right)$ and on statins $\left(A_{0}=1\right)$ at baseline. The $A_{0}=1$ group has lower cholesterol levels compared to the $A_{0}=0$ group, suggesting participants who are on statins at baseline might have been using statins for a certain time. Therefore, we do not consider cholesterol levels at baseline in computing the IPTW weights. However, given the correlation of cognitive function with age and sex in older adults Harada et al., 2013, Murman, 2015, Levine et al., 2021, Leshchyk et al., 2023, Sebastiani et al. 2023], we apply IPTW to account for the difference in the age distributions at baseline and the sex ratio between $A_{0}=0$ and $A_{0}=1$. To compute the IPTW weights $\hat{w}^{A}$, we estimate the propensity score $\hat{p}\left(A_{0} \mid a g e\right.$, sex $)$ using a logistic regression model with age at baseline and sex as predictors. After applying IPTW to the data, the distributions of age at baseline and sex are comparable between the two groups, see the weighted baseline characteristics table (Table 5).

This application compares the survival-incorporated median cognitive change of the DSST score between baseline and 8 years in participants with a similar age-and sex distribution off/on statins, had they remained off/on statins throughout:

- Group $a=0$ : participants off statins at baseline $\left(A_{0}=0\right)$, had they remained off statins throughout.
- Group $a=1$ : participants on statins at baseline $\left(A_{0}=1\right)$, had they remained on statins throughout.

We apply Inverse Probability of Censoring Weighting (IPCW) Robins et al., 1994 to account for censored DSST scores. We censor participants for the following reasons:

1. Participant deviated from their initial treatment (participants off statins at baseline starting statins later, and participants on statins at baseline stopping statins later).



Figure 2: Baseline cholesterol levels in those off statins at baseline $\left(A_{0}=0\right)$ and on statins at baseline $\left(A_{0}=1\right)$ in the LLFS participants with age in $[70,85)$

We assume Missing At Random (MAR, Rubin, 1976) and apply time-dependent IPCW.
2. Participant was absent for the year-8 DSST visit. We denote this as $C_{m i s s i n g}=1$ (versus $C_{\text {missing }}=0$ ). We assume MAR and apply IPCW.
3. Participant attended the year-8 DSST assessment, but the result was invalid. We denote this as $C_{\text {invalid }}=1$ (versus $C_{\text {invalid }}=0$ ). We assume Missing Completely At Random (MCAR, Rubin, 1976) and apply IPCW without including covariates.

The IPCW from 1. and 2. above are only conditioning on the baseline covariates $L_{0}$ listed in Table 4, since the covariates are only measured at baseline. Statin usage is monitored at baseline, the first visit, and the second visit. All models for IPCW are fitted separately for $A_{0}=0$ and $A_{0}=1$. For example, for those who are on statins at baseline, $A_{0}=1$, the IPCW weights $\hat{w}_{A_{0}=1}^{C}$ are:

1. If the participant is alive with valid non-missing year-8 DSST score:

$$
\begin{aligned}
& \hat{w}_{A_{0}=1}^{C}=\frac{\mathbb{1}_{\text {on statins through visit } 2}}{\prod_{k=1}^{2} P\left(\text { on statins } \mid \text { on statins }{ }_{k-1}, L_{0}, A_{0}=1, D_{k}=0\right)} \times \\
& \frac{1}{P\left(C_{\text {missing }}=0 \mid \text { on statins through visit } 2, L_{0}, A_{0}=1, D_{2}=0\right)} \times \\
& \frac{1}{P\left(C_{\text {invalid }}=0 \mid C_{\text {missing }}=0, \text { on statins through visit } 2, A_{0}=1, D_{2}=0\right)} .
\end{aligned}
$$

The first factor is used to account for deviations from the initial regimen, the second factor is used to account for missing year-8 tests, and the third factor is used to account for invalid year- 8 tests.
2. If the participant died between the $(M-1)$ th visit and the $M$ th visit, $M=1,2,3$ :

$$
\hat{w}_{A_{0}=1}^{C}=\frac{\text { on statins until death }}{\prod_{k=1}^{M-1} P\left(\text { on statins }_{t} \mid \text { on statins }{ }_{k-1}, L_{0}, A_{0}=1, D_{k}=0\right)}
$$

If the participant died between baseline and the first visit, their weight is 1 .
3. If the participant missed or had an invalid year-8 DSST, or stopped statins before the year-8 DSST:

$$
\hat{w}_{A_{0}=1}^{C}=0 .
$$

$P\left(\right.$ on statins ${ }_{t} \mid$ on statins $\left.{ }_{t-1}, L_{0}, A_{0}=1, D_{t}=0\right)$ is estimated by two logistic regression models: one for $t=1$ and one for $t=2$.
$P\left(C_{\text {missing }}=0 \mid\right.$ on statins through visit $\left.2, L_{0}, A_{0}=1, D=0\right)$ is estimated by a logistic regression model.
$P\left(C_{\text {invalid }}=0 \mid C_{\text {missing }}=0\right.$, on statins through visit $\left.2, A_{0}=1, D=0\right)$ is estimated by its empirical fraction.

The total weight for those on statins at baseline is the product of the IPTW weight and the IPCW weight, $\hat{w}^{A} \cdot \hat{w}_{A_{0}=1}^{C}$. Similarly, for those off statins at baseline, the total weight is $\hat{w}^{A} \cdot \hat{w}_{A_{0}=0}^{C}$. Equation (1) is then used to estimate the survival-incorporated medians.


Table 3: IPTW weighted baseline characteristics of LLFS participants; IPTW, Inverse Probability of Treatment Weighting; N, number; IQR, interquartile range; HDL, highdensity lipoprotein; LDL, low-density lipoprotein; $\mathrm{mg} / \mathrm{dL}$, milligrams per deciliter; $A_{0}=0$, participants off statins at baseline; $A_{0}=1$, participants on statins at baseline.

### 4.2 Results

Table 4 shows the estimated probabilities of death and the estimated survival-incorporated median cognitive change in age- and sex-comparable participants on and off statins, had they continued their initial treatment throughout. The estimated differences between the survival-incorporated cognitive change of participants on and off statins are relatively small, considering that the DSST scores ranges from 0 to 100 . The $95 \%$ confidence intervals for the difference (calculated by bootstrap percentile method Efron, 1992) include zero. In particular, for age group $55-69$, the confidence interval $[-1,1]$ is relatively narrow. Therefore, our results indicate no statistically or clinically significant difference of the change in cognitive function incorporating death between the participants on statins $(a=0)$ and the participants off statins ( $a=1$ ).

|  |  | Estimated \% of death $(95 \% \mathrm{CI})$ | Survival-incorporated median $(95 \% \mathrm{CI})$ |
| :---: | :---: | :---: | :---: |
| age 55-69 | $a=0$ | 4.7\% (3.6\%, 5.7\%) | -4 [-4, -3] |
|  | $a=1$ | $3.8 \%$ (1.7\%, 6.4\%) | -4 [-5, -3] |
|  | $a=1-a=0$ | -0.9\% (-3.4\%, 1.9\%) | $0[-1,1]$ |
| age 70-84 | $a=0$ | 18.2\% (14.4\%, 22.6\%) | -8 [-9, -6] |
|  | $a=1$ | 14.8\% (9.7\%, 20.4\%) | -7 [-9, -5] |
|  | $a=1-a=0$ | $-2.8 \%(-9.3 \%, 4.6 \%)$ | $1[-2,4]$ |

Table 4: Probabilities of death and the survival-incorporated median cognitive change with bootstrap $95 \%$ confidence intervals (CIs). Results are estimated with Inverse Probability of Treatment Weighting (IPTW) and Inverse Probability of Censoring Weighting (IPCW), ensuring participants are age-and sex- comparable. $a=0$ : participants off statins at baseline, had they remained off statins throughout. $a=1$ : participants on statins at baseline, had they remained on statins throughout.

## 5 Statistical properties of the survival-incorporated quantile estimated from observational data

Theorem 1 below states that the survival-incorporated $\tau$ th quantile of the outcome is identifiable from observational data. Theorem 1 generalizes Lemma 1 in Firpo 2007 from point-treatment settings to time-varying treatment settings with $K+1$ follow-up times. Appendix A. 1 provides the proof of Theorem 1.

Theorem 1 (Identification of quantiles) Under Assumptions 1-4, the $\tau$ th quantile of the composite outcome $\tilde{Y}$ under treatment regimen $\bar{a}_{K}, q_{\tau}^{\left(\bar{a}_{K}\right)}$, can be expressed as an implicit function of the observed data:

$$
E\left(\frac{\mathbb{1}_{\bar{A}_{K}=\bar{a}_{K}}}{\prod_{k=0}^{K} P\left[A_{k}=a_{k} \mid \bar{A}_{k-1}=\bar{a}_{k-1}, \bar{L}_{k}\right]} \cdot\left(\mathbb{1}_{\tilde{Y} \leq q_{\tau}^{\left(\bar{a}_{K}\right)}}-\tau\right)\right)=0 .
$$

For both point-treatment $a$ and time-varying treatment $\bar{a}$, Theorem 2 below states that the IPTW-estimated $\tau$ th quantile is consistent for the true population survival-incorporated quantile. Let $\tilde{q}_{\tau}^{(a)}$ denote the $\tau$ th quantile estimated with the known propensity score. Theorem 3 below states that $\tilde{q}_{\tau}^{(a)}$ is asymptotically normal. Appendix includes regularity conditions and proofs for consistency (Appendix A.2) and asymptotic normality (Appendix A.3).

Theorem 2 (Consistency) Under Assumptions 1-4 and regularity conditions 5-9 of Appendix,

$$
\begin{aligned}
& \hat{q}_{\tau}^{(a)} \xrightarrow{P} q_{\tau}^{(a)}, \\
& \hat{q}_{\tau}^{(\bar{a})} \xrightarrow{P} q_{\tau}^{(\bar{a})} .
\end{aligned}
$$

Theorem 3 (Asymptotic normality with known propensity score) Under Assumptions 1-4 and regularity conditions 5-9 of Appendix,

$$
\sqrt{N}\left(\tilde{q}_{\tau}^{(a)} \rightarrow q_{\tau}^{(a)}\right) \xrightarrow{\mathcal{D}} N\left(0, \frac{\tilde{V}}{f_{Y^{(a)}}^{2}\left(q_{\tau}^{(a)}\right)}\right)
$$

where

$$
\tilde{V}=E\left\{\left[\frac{\mathbb{1}_{A=a}}{P(A=a \mid L)}\left(\mathbb{1}_{Y \leq q_{\tau}^{(a)}}-\tau\right)\right]^{2}\right\} .
$$

Let $\theta$ denotes the parameters of the model used to estimate the propensity score. When the propensity score is estimated, Theorem 4 below states that $\hat{q}_{\tau}^{(a)}$ is asymptotically normal. Appendix Section A. 4 provides the proof of Theorem 4.

Theorem 4 (Asymptotic normality with estimated propensity score) Under Assumptions 1-4 and regularity conditions 5-9 of Appendix,

$$
\sqrt{N}\left(\hat{q}_{\tau}^{(a)} \rightarrow q_{\tau}^{(a)}\right) \xrightarrow{\mathcal{D}} N\left(0, \frac{V}{f_{Y^{(a)}}^{2}\left(q_{\tau}^{(a)}\right)}\right),
$$

where

$$
V=E\left\{\left[\frac{\mathbb{1}_{A_{i}=a}}{P\left(A_{i}=a \mid L_{i}\right)}\left(\mathbb{1}_{Y_{i} \leq q_{\tau}^{(a)}}-\tau\right)\right]^{2}\right\}-D^{\top} I\left(\theta^{*}\right)^{-1} D
$$

with $I\left(\theta^{*}\right)$ the partial Fisher information for $\theta$ and

$$
D=E\left(\mathbb{1}_{A_{i}=1} L_{i}\left(1-\frac{1}{p_{\theta^{*}}\left(A_{i}=1 \mid L_{i}\right)}\right)\left(\mathbb{1}_{Y_{i} \leq q_{\tau}^{(1)}}-\tau\right)\right)
$$

Theorem 3 and Theorem 4 show that the estimator based on the estimated propensity score is more efficient, as was also seen for estimating means Robins et al., 1994.

## 6 Simulation study

We investigate the performance of the proposed IPTW quantile estimator for the survivalincorporated median in simulation studies.

### 6.1 Point-treatment setting

Consider an observational point-treatment setting with a binary baseline confounder $L$. After observing $A$ based on $L$, for each individual we observe whether patients died ( $D=1$ ) or are alive ( $D=0$ ), and if $D=0$ we observe a continuous clinical outcome $Y$ (Figure 3). In this simulation setting, treatment $a=1$ improves survival but has a lower clinical outcome $Y$ in the survivors; we simulate the clinical outcome for those who survive by

$$
Y=-0.9 A+3 L+\varepsilon
$$

where $\varepsilon \sim N(0,1)$.


Figure 3: Simulation scenario for a point-treatment setting with observational data

For this simulation setting, Appendix B. 1 provides a mathematical derivation of the true population survival-incorporated median and the median in the survivors under both $a=0$ and $a=1$. The true population survival-incorporated median is 0.328 under $a=0$ and 0.606 under $a=1$. The true population median in the survivors is 1.907 under $a=0$ and 1.089 under $a=1$. Hence, the survival-incorporated median and the median in the survivors lead to different conclusions.

### 6.2 Time-varying setting

Consider a simulated time-varying setting with two follow-up times (Appendix Figure B1). $L_{k}$ is a binary covariate for $k=0,1$. After observing treatment $A_{0}$ based on baseline covariate $L_{0}$, we observe whether patients died, and if $D_{1}=0$ we observe covariate $L_{1}$ at the first follow-up time. At the second follow-up time, we observe whether patients died, and if $D_{2}=0$ we observe the clinical outcome $Y$. We simulate the final clinical outcome
for those who survive by

$$
Y=2 L_{0}-0.4 A_{0}+2.2 L_{1}-0.4 A_{1}+\varepsilon
$$

where $\varepsilon \sim N(0,1)$. The distribution of $L_{k}, A_{k}$, and $D_{k}$ all depend on the covariate and treatment history:

$$
\begin{aligned}
& P\left(L_{0}=1\right)=0.6, P\left(A_{0}=1 \mid L_{0}=0\right)=0.3, P\left(A_{0}=1 \mid L_{0}=1\right)=0.7 \\
& \operatorname{logit}\left(P\left(D_{1}=1 \mid L_{0}, A_{0}\right)\right)=-0.8+0.5 L_{0}-0.8 A_{0} \\
& \operatorname{logit}\left(P\left(L_{1}=1 \mid L_{0}, A_{0}, D_{1}=0\right)\right)=-1+2 L_{0}-A_{0} \\
& \operatorname{logit}\left(P\left(A_{1}=1 \mid A_{0}, L_{0}, D_{1}=0, L_{1}\right)\right)=-2.5+0.8 L_{0}+3 A_{0}+L_{1} \\
& \operatorname{logit}\left(P\left(D_{2}=1 \mid L_{0}, A_{0}, D_{1}=0, L_{1}, A_{1}\right)\right)=-1.8+0.3 L_{0}-0.4 A_{0}+0.5 L_{1}-0.6 A_{1} .
\end{aligned}
$$

The coefficients in the above equations ensure that the probabilities of death under each treatment regimen are below $50 \%$.

We focus on two treatment regimens of interest: $\bar{a}=(0,0)$ versus $\bar{a}=(1,1)$. The true survival-incorporated median is 0.339 under $\bar{a}=(0,0)$ and 0.395 under $\bar{a}=(1,1)$. The true population median in the survivors is 2.281 under $\bar{a}=(0,0)$ and 0.987 under $\bar{a}=(1,1)$ (Appendix B.2). Similar to the point-treatment setting, the survival-incorporated median and the median in the survivors lead to different conclusions.

### 6.3 Simulation results

Table 5 and 6 show the results in the point-treatment setting and the time-varying setting, respectively. For each simulation scenario, 2000 datasets were generated with the number of subjects $N=500,1500,5000$. The results are based on the estimated propensity scores (for results based on the true propensity scores, see the Appendix B.3). The simulation results compare the proposed IPTW quantile estimator with an unweighted quantile estimator.

Table 5: Simulation results for estimation of the survival-incorporated median in a pointtreatment setting. Truth: True survival-incorporated median. IPTW: Inverse Probability of Treatment Weighting. rMSE: Root Mean Square Error.

|  |  | True $P$ (death) | Truth | Weighted (IPTW) estimation |  | Unweighted estimation |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
|  |  |  |  | rMSE | Bias | rMSE | Bias |
| $a=0$ | $\mathrm{N}=500$ | 0.310 | 0.328 | 0.298 | 0.006 | 0.464 | -0.429 |
|  | $\mathrm{N}=1500$ |  |  | 0.211 | 0.004 | 0.444 | -0.426 |
|  | $\mathrm{N}=5000$ |  |  | 0.093 | 0.002 | 0.428 | -0.424 |
| $a=1$ | $\mathrm{N}=500$ | 0.122 | 0.606 | 0.226 | -0.009 | 0.818 | 0.806 |
|  | $\mathrm{N}=1500$ |  |  | 0.160 | -0.007 | 0.814 | 0.808 |
|  | $\mathrm{N}=5000$ |  |  | 0.073 | -0.001 | 0.813 | 0.811 |

From the simulation results, we observe: (1) The unweighted quantile estimator for the survival-incorporated median is substantially biased. (2) The IPTW quantile estimator for the survival-incorporated median has a very small bias. (3) Both rMSE and bias decrease as the number of participants increases. (4) The estimator for the survival-incorporated median based on the estimated propensity score has a smaller rMSE than the estimator based on the true propensity score (Appendix Table B1 and B2). The results align with the theory that the estimator based on the estimated propensity score is more efficient.

Table 6: Simulation results for estimation of the survival-incorporated median in a timevarying setting. Truth: True survival-incorporated median. IPTW: Inverse Probability of Treatment Weighting. rMSE: Root Mean Square Error.

|  |  | True $P$ (death) | Truth | Weighted (IPTW) estimation |  | Unweighted estimation |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
|  |  |  |  | rMSE | Bias | rMSE | Bias |
| $\bar{a}=(0,0)$ | $\mathrm{N}=500$ | 0.356 | 0.339 | 0.425 | -0.003 | 0.277 | 0.158 |
|  | $\mathrm{N}=1500$ |  |  | 0.240 | -0.001 | 0.204 | 0.156 |
|  | $\mathrm{N}=5000$ |  |  | 0.125 | -0.002 | 0.167 | 0.151 |
| $\bar{a}=(1,1)$ | $\mathrm{N}=500$ | 0.168 | 0.395 | 0.246 | -0.009 | 1.236 | 1.219 |
|  | $\mathrm{N}=1500$ |  |  | 0.140 | -0.008 | 1.231 | 1.223 |
|  | $\mathrm{N}=5000$ |  |  | 0.076 | -0.002 | 1.224 | 1.220 |

## 7 Discussion

This article compares the cognitive change between LLFS participants off and on statins, taking into account of truncation by death. We propose an IPTW quantile estimator to estimate the survival-incorporated median from observational data. We prove consistency and asymptotic normality of the proposed estimator, and we demonstrate its performance through simulations. We apply the survival-incorporated median to estimate the change in cognitive function in participants on and off statins from baseline, taking into account of participants' death.

To estimate the survival-incorporated median, the IPTW and IPCW estimator in equation (1) may not be the only option. Most standard statistical software supports the es-
timation of a weighted quantile. For example, the "weighted_quantile" function in the R package "MetricsWeighted", as well as PROC MEANS WEIGHT statement in SAS.

In the simulation studies and the LLFS application, we compare the survival-incorporated median with the median in the survivors. Xiang et al. 2023b compare the survivalincorporated median with Survivor Average Causal Effect (SACE), a estimand focus on the population that will always survivr regardless of the treatment regimen. SACE estimands are not usually identifiable without strong assumptions. In contrast, the survivalincorporated median, which relies on fewer assumptions and is simpler to estimate, can be used as a practical tool to summarize the clinical benefit of treatments for outcomes in the presence of death Xiang et al. 2023b.

In the LLFS application, older people on statins may have worse health status. However, possible health-seeking behaviors in the participants on statins may positively influence their health status Shrank et al., 2011. Those two factors affect the health status of the participants in an opposite way.

The $95 \%$ CIs of the estimated survival-incorproated median difference are not wide and inlcude zero. Therefore, The LLFS application reveals no significant differences of change in cognitive function between participants on and off statins, taking into account of truncation by death. Nevertheless, the application demonstrates that the survival-incorporated median can be a practically useful summary measure for studies in the presence of death.

## References

Anish Adhikari, Swetapadma Tripathy, Sarah Chuzi, Jonna Peterson, and Neil J Stone. Association between statin use and cognitive function: a systematic review of randomized clinical trials and observational studies. Journal of Clinical Lipidology, 15(1):22-32, 2021.

Ahmed M Alsehli, Gaia Olivo, Laura E Clemensson, Michael J Williams, and Helgi B Schiöth. The cognitive effects of statins are modified by age. Scientific Reports, 10(1): 6187, 2020.

Krishna B Athreya and Soumendra N Lahiri. Measure theory and probability theory, volume 19. Springer, 2006.

Juliín Benito-León, Elan D Louis, Saturio Vega, and Félix Bermejo-Pareja. Statins and cognitive functioning in the elderly: a population-based study. Journal of Alzheimer's Disease, 21(1):95-102, 2010.

Elizabeth Colantuoni, Daniel O Scharfstein, Chenguang Wang, Mohamed D Hashem, Andrew Leroux, Dale M Needham, and Timothy D Girard. Statistical methods to compare functional outcomes in randomized controlled trials with high mortality. bmj, 360, 2018.

Rick Durrett. Probability: theory and examples, volume 49. Cambridge university press, 2019.

Bradley Efron. Bootstrap methods: another look at the jackknife. In Breakthroughs in statistics, pages 569-593. Springer, 1992.

Sergio Firpo. Efficient semiparametric estimation of quantile treatment effects. Econometrica, 75(1):259-276, 2007.

Caroline N Harada, Marissa C Natelson Love, and Kristen L Triebel. Normal cognitive aging. Clinics in geriatric medicine, 29(4):737-752, 2013.

Miguel Hernan and James M. Robins. Causal Inference: What If. Boca Raton: Chapman \& Hall/CRC, 2020.

Miguel Ángel Hernán, Babette Brumback, and James M Robins. Marginal structural models to estimate the causal effect of zidovudine on the survival of hiv-positive men. Epidemiology, pages 561-570, 2000.

Joseph W Hogan and Joo Yeon Lee. Marginal structural quantile models for longitudinal observational studies with time-varying treatment. Statistica Sinica, pages 927-944, 2004.

YH Joshua Chen, A Lawrence Gould, and Michael L Nessly. Treatment comparisons for a partially categorical outcome applied to a biomarker with assay limit. Statistics in medicine, 24(2):211-228, 2005.

Roger Koenker and Gilbert Bassett. Regression quantiles. Econometrica: journal of the Econometric Society, pages 33-50, 1978.

John M Lachin. Worst-rank score analysis with informatively missing observations in clinical trials. Controlled clinical trials, 20(5):408-422, 1999.

Anastasia Leshchyk, Qingyan Xiang, Stacy L Andersen, Anastasia Gurinovich, Zeyuan Song, Joseph H Lee, Kaare Christensen, Anatoliy Yashin, Mary Wojczynski, Karen Schwander, et al. Mosaic chromosomal alterations and human longevity. The Journals of Gerontology: Series A, 78(9):1561-1568, 2023.

Deborah A Levine, Alden L Gross, Emily M Briceño, Nicholas Tilton, Bruno J Giordani, Jeremy B Sussman, Rodney A Hayward, James F Burke, Stephanie Hingtgen, Mitchell SV Elkind, et al. Sex differences in cognitive decline among us adults. JAMA network open, 4(2):e210169-e210169, 2021.

Judith J Lok, Ronald J Bosch, Constance A Benson, Ann C Collier, Gregory K Robbins, Robert W Shafer, and Michael D Hughes. Long-term increase in cd4+ t-cell counts
during combination antiretroviral therapy for hiv-1 infection. AIDS (London, England), 24(12):1867, 2010.

Matthew F Muldoon, Steven D Barger, Christopher M Ryan, Janine D Flory, John P Lehoczky, Karen A Matthews, and Stephen B Manuck. Effects of lovastatin on cognitive function and psychological well-being. The American journal of medicine, 108(7):538546, 2000.

Daniel L Murman. The impact of age on cognition. In Seminars in hearing, volume 36, pages 111-121. Thieme Medical Publishers, 2015.

TE Murphy, L Han, HG Allore, PN Peduzzi, TM Gill, and H Lin. Treatment of death in the analysis of longitudinal studies of gerontological outcomes. Journals of Gerontology Series A: Biomedical Sciences and Medical Sciences, 66(1):109-114, 2011.

Elena Olmastroni, Giulia Molari, Noemi De Beni, Ornella Colpani, Federica Galimberti, Marta Gazzotti, Alberto Zambon, Alberico L Catapano, and Manuela Casula. Statin use and risk of dementia or alzheimer's disease: A systematic review and meta-analysis of observational studies. European journal of preventive cardiology, 29(5):804-814, 2022.

Brian R Ott, Lori A Daiello, Issa J Dahabreh, Beth A Springate, Kimberly Bixby, Manjari Murali, and Thomas A Trikalinos. Do statins impair cognition? a systematic review and meta-analysis of randomized controlled trials. Journal of general internal medicine, 30: 348-358, 2015.

Bojana Petek, Henrike Häbel, Hong Xu, Marta Villa-Lopez, Irena Kalar, Minh Tuan Hoang, Silvia Maioli, Joana B Pereira, Shayan Mostafaei, Bengt Winblad, et al. Statins and cognitive decline in patients with alzheimer's and mixed dementia: a longitudinal registrybased cohort study. Alzheimer's Research \& Therapy, 15(1):220, 2023.

James M Robins. A new approach to causal inference in mortality studies with a sustained exposure period-application to control of the healthy worker survivor effect. Mathematical modelling, 7(9-12):1393-1512, 1986.

James M Robins, Andrea Rotnitzky, and Lue Ping Zhao. Estimation of regression coefficients when some regressors are not always observed. Journal of the American statistical Association, 89(427):846-866, 1994.

James M Robins, Miguel Angel Hernan, and Babette Brumback. Marginal structural models and causal inference in epidemiology. Epidemiology, 11(5):550-560, 2000.

Kenneth J Rothman, Sander Greenland, Timothy L Lash, et al. Modern epidemiology, volume 3. Wolters Kluwer Health/Lippincott Williams \& Wilkins Philadelphia, 2008.

Donald B Rubin. Inference and missing data. Biometrika, 63(3):581-592, 1976.

Bob G Schultz, Denise K Patten, and Daniel J Berlau. The role of statins in both cognitive impairment and protection against dementia: a tale of two mechanisms. Translational neurodegeneration, 7:1-11, 2018.

Paola Sebastiani, Zeyuan Song, Dylan Ellis, Qu Tian, Michaela Schwaiger-Haber, Ethan Stancliffe, Michael S Lustgarten, Cory C Funk, Priyanka Baloni, Cong-Hui Yao, et al. A metabolomic signature of the apoe2 allele. GeroScience, 45(1):415-426, 2023.

Ben Sherwood, Lan Wang, and Xiao-Hua Zhou. Weighted quantile regression for analyzing health care cost data with missing covariates. Statistics in medicine, 32(28):4967-4979, 2013.

William H Shrank, Amanda R Patrick, and M Alan Brookhart. Healthy user and related bi-
ases in observational studies of preventive interventions: a primer for physicians. Journal of general internal medicine, 26:546-550, 2011.

Chenguang Wang, Daniel O Scharfstein, Elizabeth Colantuoni, Timothy D Girard, and Ying Yan. Inference in randomized trials with death and missingness. Biometrics, 73 (2):431-440, 2017.

David Wechsler. Wechsler adult intelligence scale-. Frontiers in Psychology, 1981.

Mary K Wojczynski, Shiow Jiuan Lin, Paola Sebastiani, Thomas T Perls, Joseph Lee, Alexander Kulminski, Anne Newman, Joe M Zmuda, Kaare Christensen, and Michael A Province. Nia long life family study: Objectives, design, and heritability of cross-sectional and longitudinal phenotypes. The Journals of Gerontology: Series A, 77(4):717-727, 2022.

Qingyan Xiang, Stacy L Andersen, Benjamin Sweigart, Sophia Gunn, Marianne Nygaard, Thomas T Perls, and Paola Sebastiani. Signatures of neuropsychological test results in the long life family study: A cluster analysis. Journal of Alzheimer's Disease, 93(4): 1457-1469, 2023a.

Qingyan Xiang, Ronald J Bosch, and Judith J Lok. The survival-incorporated median vs the median in the survivors or in the always-survivors: What are we measuring? and why? Statistics in Medicine, 42(29):5479-5490, 2023b.

Hangying Ying, Jiacheng Wang, Zhida Shen, Meihui Wang, and Binquan Zhou. Impact of lowering low-density lipoprotein cholesterol with contemporary lipid-lowering medicines on cognitive function: a systematic review and meta-analysis. Cardiovascular Drugs and Therapy, 35:153-166, 2021.

Zhiwei Zhang, Zhen Chen, James F Troendle, and Jun Zhang. Causal inference on quantiles with an obstetric application. Biometrics, 68(3):697-706, 2012.

## APPENDIX

## A Proofs

## A. 1 Proof of Theorem 1: identification of quantiles

We first show that on the event $\bar{A}_{K}=\bar{a}_{K}$,

$$
\begin{equation*}
P\left[\bar{A}_{k}=\bar{a}_{k} \mid \bar{L}_{K}^{\left(\bar{a}_{K}\right)}=\bar{l}_{K}, Y^{\left(\bar{a}_{K}\right)}\right]=\prod_{k=0}^{K} P\left[A_{k}=a_{k} \mid \bar{A}_{k-1}=\bar{a}_{k-1}, \bar{L}_{k}=\bar{l}_{k}\right], \tag{A1}
\end{equation*}
$$

as follows:

$$
\begin{aligned}
& \quad P\left[A_{0}=a_{0}, A_{1}=a_{1}, \ldots, A_{K}=a_{K} \mid \bar{L}_{K}^{\left(\bar{a}_{K}\right)}=\bar{l}_{K}, Y^{\left(\bar{a}_{K}\right)}\right] \\
& =P\left[A_{0}=a_{0} \mid \bar{L}_{K}^{\left(\bar{a}_{K}\right)}=\bar{l}_{K}, Y^{\left(\bar{a}_{K}\right)}\right] \times P\left[A_{1}=a_{1} \mid A_{0}=a_{0}, \bar{L}_{K}^{\left(\bar{a}_{K}\right)}=\bar{l}_{K}, Y^{\left(\bar{a}_{K}\right)}\right] \\
& \\
& \quad \times P\left[A_{K}=a_{K} \mid \bar{A}_{K-1}=\bar{a}_{K-1}, \bar{L}_{K}^{\left(\bar{a}_{K}\right)}=\bar{l}_{K}, Y^{\left(\bar{a}_{K}\right)}\right] \\
& =P\left[A_{0}=a_{0} \mid L_{0}=l_{0}, \bar{L}_{K}^{\left(\bar{a}_{K}\right)}=\bar{l}_{K}, Y^{\left(\bar{a}_{K}\right)}\right] \\
& \\
& \quad \times P\left[A_{1}=a_{1} \mid A_{0}=a_{0}, \bar{L}_{1}=\bar{l}_{1}, \bar{L}_{K}^{\left(\bar{a}_{K}\right)}=\bar{l}_{K}, Y^{\left(\bar{a}_{K}\right)}\right] \\
& \\
& \quad \times P\left[A_{K}=a_{K} \mid \bar{A}_{K-1}=\bar{a}_{K-1}, \bar{L}_{K}=\bar{l}_{K}, Y^{\left(\bar{a}_{K}\right)}\right] \\
& =P\left[A_{0}=a_{0} \mid L_{0}=l_{0}\right] \times P\left[A_{1}=a_{1} \mid A_{0}=a_{0}, \bar{L}_{1}=\bar{l}_{1}\right] \\
& \quad \cdots P\left[A_{K}=a_{K} \mid \bar{A}_{K-1}=\bar{a}_{K-1}, \bar{L}_{K}=\bar{l}_{K}\right] \\
& =\prod_{k=0}^{K} P\left[A_{k}=a_{k} \mid \bar{A}_{k-1}=\bar{a}_{k-1}, \bar{L}_{k}=\bar{l}_{k}\right] .
\end{aligned}
$$

The second equality uses Consistency (Assumption 2) on the event $\bar{A}_{K}=\bar{a}_{K}$, and the third equality uses No Unmeasured Confounding (Assumption 1).

We use equation (A1) to prove Theorem 1:

$$
\begin{aligned}
& E\left(\frac{\mathbb{1}_{\bar{A}_{K}=\bar{a}_{K}}}{\prod_{k=0}^{K} P\left[A_{k}=a_{k} \mid \bar{A}_{k-1}=\bar{a}_{k-1}, \bar{L}_{k}\right]} \cdot\left(\mathbb{1}_{Y \leq q_{\tau}^{\left(\bar{a}_{K}\right)}}-\tau\right)\right) \\
= & E\left(\frac{\mathbb{1}_{\bar{A}_{K}=\bar{a}_{K}}}{\prod_{k=0}^{K} P\left[A_{k}=a_{k} \mid \bar{A}_{k-1}=\bar{a}_{k-1}, \bar{L}_{k}\right]} \cdot\left(\mathbb{1}_{Y^{\left(\bar{a}_{K}\right)} \leq q_{\tau}^{\left(\bar{a}_{K}\right)}}-\tau\right)\right) \\
= & E\left(E\left[\left.\frac{\mathbb{1}_{\bar{A}_{K}=\bar{a}_{K}}}{\prod_{k=0}^{K} P\left[A_{k}=a_{k} \mid \bar{A}_{k-1}=\bar{a}_{k-1}, \bar{L}_{k}\right]} \cdot\left(\mathbb{1}_{Y^{\left(\bar{a}_{K}\right)} \leq q_{\tau}^{\left(\bar{a}_{K}\right)}}-\tau\right) \right\rvert\, \bar{L}_{K}^{\left(\bar{a}_{K}\right)}, Y^{\left(\bar{a}_{K}\right)}\right]\right) \\
= & E\left(\frac{E\left[\mathbb{1}_{\bar{A}_{K}=\bar{a}_{K}} \mid \bar{L}_{K}^{\left(\bar{a}_{K}\right)}, Y^{\left(\bar{a}_{K}\right)}\right]}{\prod_{k=0}^{K} P\left[A_{k}=a_{k} \mid \bar{A}_{k-1}=\bar{a}_{k-1}, \bar{L}_{k}\right]} \cdot\left(\mathbb{1}_{\left.Y^{\left(\bar{a}_{K}\right) \leq q_{\tau}^{(\bar{a}} K}\right)}-\tau\right)\right) \\
= & E\left(\frac{P\left[\bar{A}_{k}=\bar{a}_{k} \mid \bar{L}_{K}^{\left(\bar{a}_{K}\right)}, Y^{\left(\bar{a}_{K}\right)}\right]}{\prod_{k=0}^{K} P\left[A_{k}=a_{k} \mid \bar{A}_{k-1}=\bar{a}_{k-1}, \bar{L}_{k}\right]}\left(\mathbb{1}_{\left.\left.Y^{\left(\bar{a}_{K}\right) \leq q_{\tau}^{\left(\bar{a}_{K}\right)}}-\tau\right)\right)}\right)\right. \\
= & E\left(\frac{\prod_{k=0}^{K} P\left[A_{k}=a_{k} \mid \bar{A}_{k-1}=\bar{a}_{k-1}, \bar{L}_{k}\right]}{\prod_{k=0}^{K} P\left[A_{k}=a_{k} \mid \bar{A}_{k-1}=\bar{a}_{k-1}, \bar{L}_{k}\right]}\left(\mathbb{1}_{Y^{\left(\bar{a}_{K}\right) \leq q_{\tau}^{\left(\bar{a}_{K}\right)}}}-\tau\right)\right) \\
= & E\left(\mathbb{1}_{\left.Y^{\left(\bar{a}_{K}\right)} \leq q_{\tau}^{\left(\bar{a}_{K}\right)}-\tau\right)}=F_{Y^{\left(\bar{a}_{K}\right)}}\left(q_{\tau}^{\left(\bar{a}_{K}\right)}\right)-\tau\right. \\
= & 0 .
\end{aligned}
$$

The first equality uses Consistency (Assumption 2). The second equality uses the Law of Iterated Expectations. The fifth equality uses equation A1). The final equality uses the definition of the quantile $q_{\tau}^{\left(\bar{a}_{K}\right)}$.

## A. 2 Proof of Theorem 2: consistency

We require additional assumptions to prove the Theorem 2, Theorem 3, and Theorem 4.

Assumption 5 The logistic regression model $\operatorname{logit}\left(p_{\theta}\left(A_{i}=a \mid L_{i}\right)\right)=\theta^{\top} L_{i}$ to estimate the propensity score is correctly specified, with $\theta^{*}$ the true parameter. $\theta^{*} \in \Theta$ with $\Theta \subset \mathbb{R}^{p}$ a
compact space.

Assumption 6 For point-treatment, $P\left(A_{i}=a \mid L_{i}=l\right)$ is uniformly bounded away from zero, i.e., there exist an $\varepsilon>0$ such that for all $l$, $\varepsilon \leq P\left(A_{i}=a \mid L_{i}=l\right) \leq 1-\varepsilon$.

Assumption 7 For time-varying treatment, $P\left(A_{k}=a_{k} \mid \bar{A}_{k-1}=\bar{a}_{k-1}, \bar{L}_{k}=\bar{l}_{k}\right)$ is uniformly bounded away from zero, i.e., there exist an $\varepsilon>0$ such that for all $\left(\bar{a}_{k-1}, \bar{l}_{k}\right)$, $\varepsilon \leq P\left(A_{k}=a_{k} \mid \bar{A}_{k-1}=\bar{a}_{k-1}, \bar{L}_{k}=\bar{l}_{k}\right) \leq 1-\varepsilon$.

Assumption 8 There exists a compact set $G \subset \mathbb{R}^{p}$ such that $P\left(L_{i} \in G\right)=1$.

Assumption 9 The density function of $Y, f_{Y}(y)$, is bounded away from 0 in an open neighborhood of $q_{\tau}$.

To prove Theorem 2, we first prove the following lemma:

Lemma 1 (i) For point treatment, the estimating equation for $q_{\tau}^{(a)}$ is

$$
\begin{equation*}
\Psi_{N}(q)=\frac{1}{N} \sum_{i=1}^{N} \frac{\mathbb{1}_{A_{i}=a}}{P\left(A_{i}=a \mid L_{i}\right)}\left(\mathbb{1}_{Y_{i} \leq q}-\tau\right)=0 \tag{A2}
\end{equation*}
$$

Under Assumption 6, this estimating equation has an almost-zero root $\hat{q}_{\tau}^{(a)}$.
(ii) For time-varying treatment, the estimating equation for $q_{\tau}^{(\bar{a})}$ is

$$
\begin{equation*}
\bar{\Psi}_{N}(q)=\frac{1}{N} \sum_{i=1}^{N} \frac{\mathbb{1}_{\bar{A}_{K}=\bar{a}_{K}}}{\prod_{k=0}^{K} \hat{P}\left[A_{k}=a_{k} \mid \bar{A}_{k-1}=\bar{a}_{k-1}, \bar{L}_{k}\right]}\left(\mathbb{1}_{Y \leq q}-\tau\right)=0 . \tag{A3}
\end{equation*}
$$

Under Assumption 7 , this estimating equation has an almost-zero root $\hat{q}_{\tau}^{(\bar{a})}$.

Proof of Lemma 1:

$$
\begin{aligned}
\Psi_{N}(q) & =\frac{1}{N} \sum_{i=1}^{N} \frac{\mathbb{1}_{A_{i}=a}}{\hat{P}\left(A_{i}=a \mid L_{i}\right)}\left(\mathbb{1}_{Y_{i} \leq q}-\tau\right) \\
& =\frac{1}{N} \sum_{i=1}^{N} \frac{\mathbb{1}_{A_{i}=a}}{\hat{P}\left(A_{i}=a \mid L_{i}\right)} \mathbb{1}_{Y_{i} \leq q}-\frac{1}{N} \sum_{i=1}^{N} \frac{\mathbb{1}_{A_{i}=a}}{\hat{P}\left(A_{i}=a \mid L_{i}\right)} \tau .
\end{aligned}
$$

The second term does not depend on $q$. The first term does depend on $q$.
$\Psi_{N}(q)$ is increasing in $q$. Small $q$ make the first term smaller than the second term, so $\Psi_{N}(q)$ is negative. Large $q$ make the first term larger than the second term, so $\Psi_{N}(q)$ is positive. Each time we increase $q$ to make $\Psi_{N}(q)$ larger by passing one of the $Y_{i}$ with $A_{i}=a, \Psi_{N}(q)$ will increase by $\mathbb{1}_{A_{i}=a} /\left(N \cdot \hat{P}\left(A_{i}=a \mid L_{i}\right)\right)$.

Since we assume that the logistic regression model for $P\left(A_{i}=a \mid L_{i}=l\right)$ is correctly specified (Assumption 5), by the asymptotic properties of the logistic regression estimator,

$$
\sup _{l}\left\|\hat{P}\left(A_{i}=a \mid L_{i}=l\right)-P\left(A_{i}=a \mid L_{i}=l\right)\right\| \xrightarrow{P} 0
$$

as $N \rightarrow \infty$.
Let $\delta>0$ be given. Choose $N$ such that for $\varepsilon>0$ from Assumption 6, there exist a $\delta>0$, for all $n \geq N$

$$
P\left(\sup _{l}\left|\hat{P}\left(A_{i}=a \mid L_{i}=l\right)-P\left(A_{i}=a \mid L_{i}=l\right)\right|<\frac{\varepsilon}{2}\right)>1-\delta .
$$

Since $\varepsilon \leq P\left(A_{i}=a \mid L_{i}\right) \leq 1-\varepsilon$ (Assumption 6), it follows that

$$
P\left(\frac{\varepsilon}{2} \leq \hat{P}\left(A_{i}=a \mid L_{i}\right) \leq 1-\frac{\varepsilon}{2}\right)>1-\delta .
$$

Therefore, the jumps of $\Psi_{N}(q)$, given by $\mathbb{1}_{A_{i}=a} /\left(N \cdot \hat{P}\left(A_{i}=a \mid L_{i}\right)\right)$, are bounded by

$$
\frac{1}{N} \cdot \frac{1}{\varepsilon / 2}
$$

with probability $>1-\delta$.
Consequently, equation (A2) has an almost zero root $\hat{q}$, because with probability $>1-\delta$, we can find $\hat{q}$ with

$$
\left|\frac{1}{N} \sum_{i=1}^{N} \frac{\mathbb{1}_{A_{i}=a}}{\hat{P}\left(A_{i}=a \mid L_{i}\right)}\left(\mathbb{1}_{Y_{i} \leq \hat{q}}-\tau\right)\right| \leq \frac{1}{N \cdot \varepsilon / 2} \rightarrow 0
$$

Following a similar procedure, it can be showed that equation (A3) also has an almost zero root $\hat{q}$.

Proof of Theorem 2 using Lemma 1:
Because of Lemma 1,

$$
\Psi_{N}(q)=\frac{1}{N} \sum_{i=1}^{N} \frac{\mathbb{1}_{A_{i}=a}}{\hat{P}\left(A_{i}=a \mid L_{i}\right)}\left(\mathbb{1}_{Y_{i} \leq q}-\tau\right)=0
$$

has an almost zero root $\hat{q}_{\tau}^{(a)}$.
To use Lemma 5.10 in Van der Vaart (2000) to prove Theorem 3, we further need to show that for all $q, \Psi_{N}(q) \xrightarrow{P} F_{Y^{(a)}}(q)-\tau$.

$$
\begin{align*}
& \Psi_{N}(q)-\left(F_{Y^{(a)}}(q)-\tau\right) \\
= & \left(\frac{1}{N} \sum_{i=1}^{N} \frac{\mathbb{1}_{A_{i}=a}}{\hat{P}\left(A_{i}=a \mid L_{i}=l\right)} \mathbb{1}_{Y_{i} \leq q}-F_{Y^{(a)}}(q)\right)-\left(\frac{1}{N} \sum_{i=1}^{N} \frac{\mathbb{1}_{A_{i}=a}}{\hat{P}\left(A_{i}=a \mid L_{i}=l\right)} \mathbb{1}_{Y_{i} \leq q}-1\right) \tau . \tag{A4}
\end{align*}
$$

In Equation (A4), for the first term, with probability $>1-\delta$,

$$
\begin{aligned}
& \left|\frac{1}{N} \sum_{i=1}^{N} \frac{\mathbb{1}_{A_{i}=a}}{\hat{P}\left(A_{i}=a \mid L_{i}=l\right)} \mathbb{1}_{Y_{i} \leq q}-F_{Y^{(a)}}(q)\right| \\
& \leq\left|\frac{1}{N} \sum_{i=1}^{N} \frac{\mathbb{1}_{A_{i}=a}}{\hat{P}\left(A_{i}=a \mid L_{i}=l\right)} \mathbb{1}_{Y_{i} \leq q}-\frac{1}{N} \sum_{i=1}^{N} \frac{\mathbb{1}_{A_{i}=a}}{P\left(A_{i}=a \mid L_{i}=l\right)} \mathbb{1}_{Y_{i} \leq q}\right| \\
& +\left|\frac{1}{N} \sum_{i=1}^{N} \frac{\mathbb{1}_{A_{i}=a}}{P\left(A_{i}=a \mid L_{i}=l\right)} \mathbb{1}_{Y_{i} \leq q}-F_{Y^{(a)}}(q)\right| \\
& =\left|\frac{1}{N} \sum_{i=1}^{N} \frac{P\left(A_{i}=a \mid L_{i}=l\right)-\hat{P}\left(A_{i}=a \mid L_{i}=l\right)}{\hat{P}\left(A_{i}=a \mid L_{i}=l\right) P\left(A_{i}=a \mid L_{i}=l\right)} \mathbb{1}_{Y_{i} \leq q}\right| \\
& +\left|\frac{1}{N} \sum_{i=1}^{N} \frac{\mathbb{1}_{A_{i}=a}}{P\left(A_{i}=a \mid L_{i}=l\right)} \mathbb{1}_{Y_{i} \leq q}-F_{Y^{(a)}}(q)\right| \\
& \leq \frac{1}{N} \sum_{i=1}^{N}\left|\frac{P\left(A_{i}=a \mid L_{i}=l\right)-\hat{P}\left(A_{i}=a \mid L_{i}=l\right)}{\hat{P}\left(A_{i}=a \mid L_{i}=l\right) P\left(A_{i}=a \mid L_{i}=l\right)} \mathbb{1}_{Y_{i} \leq q}\right| \\
& +\left|\frac{1}{N} \sum_{i=1}^{N} \frac{\mathbb{1}_{A_{i}=a}}{P\left(A_{i}=a \mid L_{i}=l\right)} \mathbb{1}_{Y_{i} \leq q}-F_{Y^{(a)}}(q)\right| \\
& <\frac{\delta / 2}{\epsilon \cdot \epsilon / 2}+\frac{\delta}{2} \\
& =\frac{\delta}{2}\left(\frac{2}{\epsilon^{2}}+1\right) \text {. }
\end{aligned}
$$

The first inequality uses Triangle Inequality. For the fourth inequality, let $\delta>0$ be given. Choose $N$ such that, for all $n \geq N$ with probability $>1-\delta / 2, \sup _{l} \mid \hat{P}\left(A_{i}=a \mid L_{i}=\right.$ $l)-P\left(A_{i}=a \mid L_{i}=l\right) \mid<\varepsilon / 2$ and $\sup _{l}\left|\hat{P}\left(A_{i}=a \mid L_{i}=l\right)-P\left(A_{i}=a \mid L_{i}=l\right)\right|<\delta / 2$. Then $\hat{P}\left(A_{i}=a \mid L_{i}=l\right) \geq \varepsilon / 2$ with probability $>1-\delta / 2$. Since

$$
\frac{1}{N} \sum_{i=1}^{N} \frac{\mathbb{1}_{A_{i}=a}}{P\left(A_{i}=a \mid L_{i}=l\right)} \mathbb{1}_{Y_{i} \leq q} \xrightarrow{P} F_{Y^{(a)}}(q),
$$

we can choose $N$ possibly even larger so that for all $n \geq N$, with probability $>1-\delta / 2$,

$$
\left|\frac{1}{N} \sum_{i=1}^{N} \frac{\mathbb{1}_{A_{i}=a}}{P\left(A_{i}=a \mid L_{i}=l\right)} \mathbb{1}_{Y_{i} \leq q}-F_{Y^{(a)}}(q)\right|<\frac{\delta}{2} .
$$

In Equation (A4), the second term can be bounded in a similar way:

$$
\begin{aligned}
& \quad\left|\frac{1}{N} \sum_{i=1}^{N} \frac{\mathbb{1}_{A_{i}=a}}{\hat{P}\left(A_{i}=a \mid L_{i}=l\right)}-1\right| \\
& \leq\left|\frac{1}{N} \sum_{i=1}^{N} \frac{\mathbb{1}_{A_{i}=a}}{\hat{P}\left(A_{i}=a \mid L_{i}=l\right)}-\frac{1}{N} \sum_{i=1}^{N} \frac{\mathbb{1}_{A_{i}=a}}{P\left(A_{i}=a \mid L_{i}=l\right)}\right| \\
& \quad+\left|\frac{1}{N} \sum_{i=1}^{N} \frac{\mathbb{1}_{A_{i}=a}}{P\left(A_{i}=a \mid L_{i}=l\right)}-1\right| \\
& =\left|\frac{1}{N} \sum_{i=1}^{N} \frac{P\left(A_{i}=a \mid L_{i}=l\right)-\hat{P}\left(A_{i}=a \mid L_{i}=l\right)}{\hat{P}\left(A_{i}=a \mid L_{i}=l\right) P\left(A_{i}=a \mid L_{i}=l\right)}\right|+\left|\frac{1}{N} \sum_{i=1}^{N} \frac{\mathbb{1}_{A_{i}=a}}{P\left(A_{i}=a \mid L_{i}=l\right)}-1\right| \\
& < \\
& <\frac{\delta}{2}\left(\frac{2}{\epsilon^{2}}+1\right) .
\end{aligned}
$$

Therefore, for all $n \geq N$, with probability $>1-\delta$,

$$
\left|\Psi_{N}(q)-\left(F_{Y^{(a)}}(q)-\tau\right)\right|<\frac{\delta}{2}\left(\frac{2}{\epsilon^{2}}+1\right)(1+\tau)
$$

By chosing $\delta>0$ small, this can be made arbitrarily small. We conclude that, as $N \rightarrow \infty$, $\Psi_{N}(q) \xrightarrow{P} F_{Y^{(a)}}(q)-\tau$.
$q \rightarrow \Psi_{N}(q)$ is nondecreasing, $\hat{q}$ is an almost zero root of $\Psi_{N}(q)$ (because of Lemma 1), and $q$ is the root of $F_{Y^{(a)}}(q)-\tau$. Therefore, Lemma 5.10 in Van der Vaart (2000) implies that

$$
\hat{q}_{\tau}^{(a)} \xrightarrow{P} q_{\tau}^{(a)} .
$$

Following a similar procedure, it can be shown that in the time-varying setting,

$$
\hat{q}_{\tau}^{(\bar{a})} \xrightarrow{P} q_{\tau}^{(\bar{a})} .
$$

## A. 3 Proof of Theorem 3: asymptotic normality when the propensity score is known

Proof:

When the propensity score is known, the estimating equation for $\tilde{q}_{\tau}^{(a)}$ (equation (2) in the main text) is

$$
\Psi_{N}(q)=\frac{1}{N} \sum_{i=1}^{N} \frac{\mathbb{1}_{A_{i}=a}}{P\left(A_{i}=a \mid L_{i}\right)}\left(\mathbb{1}_{Y_{i} \leq q}-\tau\right) .
$$

$\Psi_{N}(q)$ is a monotone increasing function in $q$. Similar to Lemma 1, there exists an almost zero root $\tilde{q}_{\tau}^{(a)}$ of $\Psi_{N}(q)$. We choose $\tilde{q}_{\tau}^{(a)}$ as the leftmost point when $\Psi_{N}(q)$ becomes positive. Since jumps are bounded by $1 /(N \varepsilon),\left|\Psi_{N}\left(\tilde{q}_{\tau}^{(a)}\right)\right| \leq 1 /(N \varepsilon)$. For this choice of $\tilde{q}_{\tau}^{(a)}$, $q$ is less than $\tilde{q}^{(a)}$, if and only if $\Psi_{N}(q)<0$. Thus, we conclude that

$$
\begin{align*}
P\left(\sqrt{N}\left(\tilde{q}_{\tau}^{(a)}-q_{\tau}^{(a)}\right)>\delta\right) & =P\left(\tilde{q}_{\tau}^{(a)}>q_{\tau}^{(a)}+\frac{\delta}{\sqrt{N}}\right) \\
& =P\left(\Psi_{N}\left(q_{\tau}^{(a)}+\frac{\delta}{\sqrt{N}}\right)<0\right) \\
& =P\left(\frac{1}{N} \sum_{i=1}^{N} \frac{\mathbb{1}_{A_{i}=a}}{P\left(A_{i}=a \mid L_{i}\right)}\left(\mathbb{1}_{Y_{i} \leq q_{\tau}^{(a)}+\frac{\delta}{\sqrt{N}}}-\tau\right)<0\right) . \tag{A5}
\end{align*}
$$

To apply the Central Limit Theorem to A5), we derive the mean and variance for the term

$$
\frac{\mathbb{1}_{A_{i}=a}}{P\left(A_{i}=a \mid L_{i}\right)}\left(\mathbb{1}_{Y_{i} \leq q_{\tau}^{(a)}+\frac{\delta}{\sqrt{N}}}-\tau\right) .
$$

As for the mean, using Theorem 1,

$$
E\left[\frac{\mathbb{1}_{A_{i}=a}}{P\left(A_{i}=a \mid L_{i}\right)}\left(\mathbb{1}_{Y_{i} \leq q_{\tau}^{(a)}+\frac{\delta}{\sqrt{N}}}-\tau\right)\right]=F_{Y^{(a)}}\left(q_{\tau}^{(a)}+\frac{\delta}{\sqrt{N}}\right)-\tau
$$

As for the variance

$$
\begin{align*}
& \operatorname{Var}\left(\frac{\mathbb{1}_{A_{i}=a}}{P\left(A_{i}=a \mid L_{i}\right)}\left(\mathbb{1}_{Y_{i} \leq q_{\tau}^{(a)}+\frac{\delta}{\sqrt{N}}}-\tau\right)\right) \\
= & E\left[\left[\frac{\mathbb{1}_{A_{i}=a}}{P\left(A_{i}=a \mid L_{i}\right)}\left(\mathbb{1}_{Y_{i} \leq q_{\tau}^{(a)}+\frac{\delta}{\sqrt{N}}}-\tau\right)\right]^{2}\right]-\left(F_{Y^{(a)}}\left(q_{\tau}^{(a)}+\frac{\delta}{\sqrt{N}}\right)-\tau\right)^{2} . \tag{A6}
\end{align*}
$$

For the first term in A6), notice that

$$
\begin{aligned}
& {\left[\frac{\mathbb{1}_{A_{i}=a}}{P\left(A_{i}=a \mid L_{i}\right)}\left(\mathbb{1}_{Y_{i} \leq q_{\tau}^{(a)}+\frac{\delta}{\sqrt{N}}}-\tau\right)\right]^{2}<=\left(\frac{\mathbb{1}_{A_{i}=a}}{P\left(A_{i}=a \mid L_{i}\right)}\right)^{2} \forall n,} \\
& E\left[\left(\frac{\mathbb{1}_{A_{i}=a}}{P\left(A_{i}=a \mid L_{i}\right)}\right)^{2}\right]<\infty .
\end{aligned}
$$

Since the denominator is bounded away from 0 (Assumption 6), so the expression in the expectation is bounded by an integrable function. In addition, as $N \rightarrow \infty$,

$$
\left[\frac{\mathbb{1}_{A_{i}=a}}{P\left(A_{i}=a \mid L_{i}\right)}\left(\mathbb{1}_{Y_{i} \leq q_{\tau}^{(a)}+\frac{\delta}{\sqrt{N}}}-\tau\right)\right]^{2} \rightarrow\left[\frac{\mathbb{1}_{A_{i}=a}}{P\left(A_{i}=a \mid L_{i}\right)}\left(\mathbb{1}_{Y_{i} \leq q_{\tau}^{(a)}}-\tau\right)\right]^{2}
$$

Therefore, Lebesgue Dominated Convergence Theorem Athreya and Lahiri, 2006 implies that

$$
E\left[\left[\frac{\mathbb{1}_{A_{i}=a}}{P\left(A_{i}=a \mid L_{i}\right)}\left(\mathbb{1}_{Y_{i} \leq q_{\tau}^{(a)}+\frac{\delta}{\sqrt{N}}}-\tau\right)\right]^{2}\right] \rightarrow E\left[\left[\frac{\mathbb{1}_{A_{i}=a}}{P\left(A_{i}=a \mid L_{i}\right)}\left(\mathbb{1}_{Y_{i} \leq q_{\tau}^{(a)}}-\tau\right)\right]^{2}\right] .
$$

For the second term in A6),

$$
F_{Y^{(a)}}\left(q_{\tau}^{(a)}+\frac{\delta}{\sqrt{N}}\right)-\tau \rightarrow F_{Y^{(a)}}\left(q_{\tau}^{(a)}\right)-\tau=0
$$

since we assumed that $F_{Y^{(a)}}\left(q_{\tau}^{(a)}\right)$ is continuous in $q$ at $q_{\tau}^{(a)}$ (Assumption 9).
Combining with equation A5), we conclude that

$$
\operatorname{Var}\left(\frac{\mathbb{1}_{A_{i}=a}}{P\left(A_{i}=a \mid L_{i}\right)}\left(\mathbb{1}_{Y_{i} \leq q_{\tau}^{(a)}+\frac{\delta}{\sqrt{N}}}-\tau\right)\right) \rightarrow E\left[\left[\frac{\mathbb{1}_{A_{i}=a}}{P\left(A_{i}=a \mid L_{i}\right)}\left(\mathbb{1}_{Y_{i} \leq q_{\tau}^{(a)}}-\tau\right)\right]^{2}\right],
$$

where we denote

$$
\tilde{V}=E\left[\left[\frac{\mathbb{1}_{A_{i}=a}}{P\left(A_{i}=a \mid L_{i}\right)}\left(\mathbb{1}_{Y_{i} \leq q_{\tau}^{(a)}}-\tau\right)\right]^{2}\right] .
$$

Now, continuing from equation A5, we subtract $F_{Y^{(a)}}\left(q_{\tau}^{(a)}+\delta / \sqrt{N}\right)-\tau$ on both sides of the inequality to obtain

$$
\begin{align*}
& P\left(\sqrt{N}\left(\tilde{q}_{\tau}^{(a)}-q_{\tau}^{(a)}\right)>\delta\right) \\
&= P\left(\frac{1}{N} \sum_{i=1}^{N} \frac{\mathbb{1}_{A_{i}=a}}{P\left(A_{i}=a \mid L_{i}\right)}\left(\mathbb{1}_{Y_{i} \leq q_{\tau}^{(a)}+\frac{\delta}{\sqrt{N}}}-\tau\right)<0\right) \\
&= P\left(\frac{1}{N} \sum_{i=1}^{N} \frac{\mathbb{1}_{A_{i}=a}}{P\left(A_{i}=a \mid L_{i}\right)}\left(\mathbb{1}_{Y_{i} \leq q_{\tau}^{(a)}+\frac{\delta}{\sqrt{N}}}-\tau\right)-\left(F_{Y^{(a)}}\left(q_{\tau}^{(a)}+\frac{\delta}{\sqrt{N}}\right)-\tau\right)\right. \\
&\left.<\tau-F_{Y^{(a)}}\left(q_{\tau}^{(a)}+\frac{\delta}{\sqrt{N}}\right)\right) \\
&= P\left(\sqrt{N}\left(\frac{1}{N} \sum_{i=1}^{N} \frac{\mathbb{1}_{A_{i}=a}}{P\left(A_{i}=a \mid L_{i}\right)}\left(\mathbb{1}_{Y_{i} \leq q_{\tau}^{(a)}+\frac{\delta}{\sqrt{N}}}-\tau\right)-\left(F_{Y^{(a)}}\left(q_{\tau}^{(a)}+\frac{\delta}{\sqrt{N}}\right)-\tau\right)\right)\right. \\
&\left.\quad<\sqrt{N}\left(\tau-F_{Y^{(a)}}\left(q_{\tau}^{(a)}+\frac{\delta}{\sqrt{N}}\right)\right)\right) . \tag{A7}
\end{align*}
$$

For the term on the right hand side of equation (A7),

$$
\begin{aligned}
& \sqrt{N}\left(\tau-F_{Y^{(a)}}\left(q_{\tau}^{(a)}+\frac{\delta}{\sqrt{N}}\right)\right) \\
= & \sqrt{N}\left(F_{Y^{(a)}}\left(q_{\tau}^{(a)}\right)-F_{Y^{(a)}}\left(q_{\tau}^{(a)}+\frac{\delta}{\sqrt{N}}\right)\right) \\
= & \sqrt{N} \cdot f_{Y^{(a)}}(\dot{q}) \cdot\left(0-\frac{\delta}{\sqrt{N}}\right) \\
\rightarrow & -\delta f_{Y^{(a)}}\left(q_{\tau}^{(a)}\right),
\end{aligned}
$$

where the second equality uses the Mean Value Theorem, and $\dot{q}$ is a value between $q_{\tau}^{(a)}$ and $q_{\tau}^{(a)}+\delta / \sqrt{N}$, and convergence follows since we assumed that $f_{Y}^{(a)}(q)$ is continuous at $q_{\tau}^{(a)}$ (Assumption 9).

Applying the Triangle Central Limit Theorem to (A7), we obtain

$$
P\left(\sqrt{N}\left(\tilde{q}_{\tau}^{(a)}-q_{\tau}^{(a)}\right)>\delta\right) \rightarrow \Phi\left(-\frac{\delta f_{Y^{(a)}}\left(q_{\tau}^{(a)}\right)}{\sqrt{\tilde{V}}}\right)
$$

which implies that

$$
P\left(\sqrt{N}\left(\tilde{q}_{\tau}^{(a)}-q_{\tau}^{(a)}\right) \leq \delta\right) \rightarrow \Phi\left(\frac{\delta f_{Y^{(a)}}\left(q_{\tau}^{(a)}\right)}{\sqrt{\tilde{V}}}\right)
$$

where $\Phi(\cdot)$ is the CDF of the standard normal distribution. We conclude that

$$
\sqrt{N}\left(\tilde{q}_{\tau}^{(a)}-q_{\tau}^{(a)}\right) \rightarrow N\left(0, \frac{\tilde{V}}{f_{Y^{(a)}}^{2}\left(q_{\tau}^{(a)}\right)}\right)
$$

## A. 4 Proof of Theorem 4: asymptotic normality when the propensity score is estimated

For asymptotic normality when the propensity score is estimated, we focus on the estimated $\tau$ th quantile under treatment $a=1$. For $a=0$, the proof follows similarly.

Proof:
For $a=1$, the estimating equation for $\hat{q}_{\tau}^{(1)}$ (equation (2) in the main text) is

$$
\Psi_{N}(q)=\frac{1}{N} \sum_{i=1}^{N} \frac{\mathbb{1}_{A_{i}=1}}{p_{\hat{\theta}}\left(A_{i}=1 \mid L_{i}\right)}\left(\mathbb{1}_{Y_{i} \leq q}-\tau\right) .
$$

$\Psi_{N}(q)$ is a monotone increasing function in $q$. From Lemma 1, there exists an almost zero root $\hat{q}_{\tau}^{(1)}$ of $\Psi_{N}(q)$. We choose $\hat{q}_{\tau}^{(1)}$ as the left-most point where $\Psi_{N}(q)$ becomes $\geq 0$. For this choise of $\hat{q}_{\tau}^{(1)}, \hat{q}_{\tau}^{(1)}$ is greater than $q$, if and only if $\Psi_{N}(q)<0$. It follows that

$$
\begin{align*}
P & \left(\sqrt{N}\left(\hat{q}_{\tau}^{(1)}-q_{\tau}^{(1)}\right)>\delta\right) \\
& =P\left(\hat{q}_{\tau}^{(1)}>q_{\tau}^{(1)}+\frac{\delta}{\sqrt{N}}\right) \\
& =P\left(\Psi_{N}\left(q_{\tau}^{(1)}+\frac{\delta}{\sqrt{N}}\right)<0\right) \\
& =P\left(\frac{1}{N} \sum_{i=1}^{N} \frac{\mathbb{1}_{A_{i}=1}}{p_{\hat{\theta}}\left(A_{i}=1 \mid L_{i}\right)}\left(\mathbb{1}_{Y_{i} \leq q_{\tau}^{(1)}+\frac{\delta}{\sqrt{N}}}-\tau\right)<0\right) . \tag{A8}
\end{align*}
$$

Because of the Mean Value Theorem,

$$
\begin{align*}
& \frac{1}{N} \sum_{i=1}^{N} \frac{\mathbb{1}_{A_{i}=1}}{p_{\hat{\theta}}\left(A_{i}=1 \mid L_{i}\right)}\left(\mathbb{1}_{Y_{i} \leq q_{\tau}^{(1)}+\frac{\delta}{\sqrt{N}}}-\tau\right) \\
& =\frac{1}{N} \sum_{i=1}^{N} \frac{\mathbb{1}_{A_{i}=1}}{p_{\theta^{*}}\left(A_{i}=1 \mid L_{i}\right)}\left(\mathbb{1}_{Y_{i} \leq q_{\tau}^{(1)}+\frac{\delta}{\sqrt{N}}}-\tau\right) \\
& \quad+\left.\frac{1}{N} \sum_{i=1}^{N} \frac{\partial}{\partial \theta}\right|_{\hat{\theta}} \frac{\mathbb{1}_{A_{i}=1}^{p_{\theta}\left(A_{i}=1 \mid L_{i}\right)}\left(\mathbb{1}_{Y_{i} \leq q_{\tau}^{(1)}+\frac{\delta}{\sqrt{N}}}-\tau\right)\left(\hat{\theta}-\theta^{*}\right),}{} \tag{A9}
\end{align*}
$$

for some $\dot{\theta}$ between $\hat{\theta}$ and $\theta^{*}$. Next, notice that $\hat{\theta}$ is estimated by maximum partial likelihood, and that it solves partial score equations of the form

$$
\mathbb{P}_{N} U_{2}(A, L ; \theta)=0
$$

where $\mathbb{P}_{N}$ is the empirical distribution, $\mathbb{P}_{N} f(A, L)=N^{-1} \sum_{i=1}^{N} f\left(A_{i}, L_{i}\right)$ for observations $\left(A_{1}, L_{1}\right), \ldots,\left(A_{N}, L_{N}\right)$, and where $U_{2}(A, L ; \theta)$ is the partial score function for $\theta$.

Then, from the theory on unbiased estimating equations, Theorem 5.21 in Van der Vaart 2000,

$$
\begin{equation*}
\sqrt{N}\left(\hat{\theta}-\theta^{*}\right)=I\left(\theta^{*}\right)^{-1} \sqrt{N} \frac{1}{N} \sum_{i=1}^{N} U_{2}\left(\theta^{*}\right)+o_{P}(1) \tag{A10}
\end{equation*}
$$

where $I\left(\theta^{*}\right)=-E\left(\left.\frac{\partial}{\partial \theta}\right|_{\theta^{*}} U_{2}(\theta)\right)$ is the partial Fisher information for $\theta$, from partial likelihood theory on estimation of $\theta$, since $U_{2}$ is the partial score for $\theta$. Combining equations (A9) and (A10), it follows that

$$
\begin{align*}
& \sqrt{N} \frac{1}{N} \sum_{i=1}^{N} \frac{\mathbb{1}_{A_{i}=1}}{p_{\hat{\theta}}\left(A_{i}=1 \mid L_{i}\right)}\left(\mathbb{1}_{Y_{i} \leq q_{\tau}^{(1)}+\frac{\delta}{\sqrt{N}}}-\tau\right) \\
& =\sqrt{N} \frac{1}{N} \sum_{i=1}^{N} \frac{\mathbb{1}_{A_{i}=1}}{p_{\theta^{*}}\left(A_{i}=1 \mid L_{i}\right)}\left(\mathbb{1}_{Y_{i} \leq q_{\tau}^{(1)}+\frac{\delta}{\sqrt{N}}}-\tau\right) \\
& +\left(\left.\frac{1}{N} \sum_{i=1}^{N} \frac{\partial}{\partial \theta}\right|_{\dot{\theta}} \frac{\mathbb{1}_{A_{i}=1}^{p_{\theta}}\left(A_{i}=1 \mid L_{i}\right)}{}\left(\mathbb{1}_{Y_{i} \leq q_{\tau}^{(1)}+\frac{\delta}{\sqrt{N}}}-\tau\right)\right) \cdot\left(I\left(\theta^{*}\right)^{-1} \sqrt{N} \frac{1}{N} \sum_{i=1}^{n} U_{2}\left(\theta^{*}\right)+o_{P}(1)\right) . \tag{A11}
\end{align*}
$$

Since the propensity score is modeled with logistic regression,

$$
p_{\theta}\left(A_{i}=1 \mid L_{i}\right)=\frac{e^{\theta L_{i}}}{1+e^{\theta L_{i}}}
$$

Hence

$$
\begin{aligned}
\frac{\partial}{\partial \theta} \frac{1}{p_{\theta}\left(A_{i}=1 \mid L_{i}\right)} & =\frac{\partial}{\partial \theta}\left(\frac{1}{e^{\theta L_{i}}}+1\right) \\
& =-L_{i} \frac{1}{e^{\theta L_{i}}} \\
& =-L_{i}\left(\frac{1+e^{\theta L_{i}}}{e^{\theta L_{i}}}-1\right) \\
& =-L_{i}\left(\frac{1}{p_{\theta}\left(A_{i}=1 \mid L_{i}\right)}-1\right) \\
& =L_{i}\left(1-\frac{1}{p_{\theta}\left(A_{i}=1 \mid L_{i}\right)}\right)
\end{aligned}
$$

Therefore, in equation A11

$$
\begin{align*}
& \left.\frac{1}{N} \sum_{i=1}^{N} \frac{\partial}{\partial \theta}\right|_{\dot{\theta}} \frac{\mathbb{1}_{A_{i}=1}^{p_{\theta}\left(A_{i}=1 \mid L_{i}\right)}\left(\mathbb{1}_{Y_{i} \leq q_{\tau}^{(1)}+\frac{\delta}{\sqrt{N}}}-\tau\right)}{\quad=\frac{1}{N} \sum_{i=1}^{N} \mathbb{1}_{A_{i}=1} L_{i}\left(1-\frac{1}{p_{\dot{\theta}}\left(A_{i}=1 \mid L_{i}\right)}\right)\left(\mathbb{1}_{Y_{i} \leq q_{\tau}^{(1)}+\frac{\delta}{\sqrt{N}}}-\tau\right)} \\
& \quad \xrightarrow{P} E\left(\mathbb{1}_{A_{i}=1} L_{i}\left(1-\frac{1}{p_{\theta^{*}}\left(A_{i}=1 \mid L_{i}\right)}\right)\left(\mathbb{1}_{Y_{i} \leq q_{\tau}^{(1)}}-\tau\right)\right) .
\end{align*}
$$

Because $L_{i}$ is in a compact space; $p_{\dot{\theta}}\left(A_{i}=1 \mid L_{i}\right)$ converges to $p_{\theta^{*}}\left(A_{i}=1 \mid L_{i}\right) ; p_{\dot{\theta}}\left(A_{i}=\right.$ $\left.1 \mid L_{i}\right)$ is bounded away from zero (Lemma 1 ); the function $1 / p_{\dot{\theta}}\left(A_{i}=1 \mid L_{i}\right)$ is continuous in $p_{\dot{\theta}}\left(A_{i}=1 \mid L_{i}\right)$. Therefore, by Continuous Mapping Theorem

$$
\mathbb{1}_{A_{i}=1} L_{i}\left(1-\frac{1}{p_{\dot{\theta}}\left(A_{i}=1 \mid L_{i}\right)}\right)\left(\mathbb{1}_{Y_{i} \leq q_{\tau}^{(1)}+\frac{\delta}{\sqrt{N}}}-\tau\right) \xrightarrow{P} \mathbb{1}_{A_{i}=1} L_{i}\left(1-\frac{1}{p_{\theta^{*}}\left(A_{i}=1 \mid L_{i}\right)}\right)\left(\mathbb{1}_{Y_{i} \leq q_{\tau}^{(1)}}-\tau\right)
$$

The equation A12 then follows from the Triangular Law of Large Numbers Durrett, 2019.

Write $D$ for the right hand side of equation A12. Combining equation (A11) and (A12) leads to

$$
\begin{aligned}
& \sqrt{N} \frac{1}{N} \sum_{i=1}^{N} \frac{\mathbb{1}_{A_{i}=1}}{p_{\hat{\theta}}\left(A_{i}=1 \mid L_{i}\right)}\left(\mathbb{1}_{Y_{i} \leq q_{\tau}^{(1)}+\frac{\delta}{\sqrt{N}}}-\tau\right) \\
&= \sqrt{N} \frac{1}{N} \sum_{i=1}^{N} \frac{\mathbb{1}_{A_{i}=1}}{p_{\theta^{*}}\left(A_{i}=1 \mid L_{i}\right)}\left(\mathbb{1}_{Y_{i} \leq q_{\tau}^{(1)}+\frac{\delta}{\sqrt{N}}}-\tau\right) \\
&+\left(D+o_{P}(1)\right) \cdot\left(I\left(\theta^{*}\right)^{-1} \sqrt{N} \frac{1}{N} \sum_{i=1}^{n} U_{2}\left(\theta^{*}\right)+o_{P}(1)\right) \\
&= \sqrt{N} \frac{1}{N} \sum_{i=1}^{N} \frac{\mathbb{1}_{A_{i}=1}}{p_{\theta^{*}}\left(A_{i}=1 \mid L_{i}\right)}\left(\mathbb{1}_{Y_{i} \leq q_{\tau}^{(1)}+\frac{\delta}{\sqrt{N}}}-\tau\right) \\
&+D I\left(\theta^{*}\right)^{-1} \sqrt{N} \frac{1}{N} \sum_{i=1}^{n} U_{2}\left(\theta^{*}\right)+o_{P}(1)
\end{aligned}
$$

Combining with equation (A8), we conclude that

$$
\begin{align*}
& P\left(\sqrt{N}\left(\hat{q}_{\tau}^{(1)}-q_{\tau}^{(1)}\right)>\delta\right) \\
&= P\left(\sqrt{N} \frac{1}{N} \sum_{i=1}^{N} \frac{\mathbb{1}_{A_{i}=1}}{p_{\theta^{*}}\left(A_{i}=1 \mid L_{i}\right)}\left(\mathbb{1}_{Y_{i} \leq q_{\tau}^{(1)}+\frac{\delta}{\sqrt{N}}}-\tau\right)\right. \\
&\left.+D I\left(\theta^{*}\right)^{-1} \sqrt{N} \frac{1}{N} \sum_{i=1}^{n} U_{2}\left(\theta^{*}\right)+o_{P}(1)<0\right) . \tag{A13}
\end{align*}
$$

To apply the Triangular Central Limit Theorem, we derive the mean, variance, and covariance for the right hand side in equation (A13) . For the term

$$
\frac{\mathbb{1}_{A_{i}=1}}{P\left(A_{i}=1 \mid L_{i}\right)}\left(\mathbb{1}_{Y_{i} \leq q_{\tau}^{(1)}+\frac{\delta}{\sqrt{N}}}-\tau\right),
$$

the mean and variance are already derived in the proof of Theorem 3. The mean is

$$
F_{Y^{(1)}}\left(q_{\tau}^{(1)}+\frac{\delta}{\sqrt{N}}\right)-\tau
$$

and it was shown that

$$
\sqrt{N}\left(F_{Y^{(1)}}\left(q_{\tau}^{(1)}+\frac{\delta}{\sqrt{N}}\right)-\tau\right) \rightarrow \delta f_{Y^{(1)}}\left(q_{\tau}^{(1)}\right)
$$

The variance was shown to converge to

$$
\tilde{V}=E\left[\left[\frac{\mathbb{1}_{A_{i}=1}}{P\left(A_{i}=1 \mid L_{i}\right)}\left(\mathbb{1}_{Y_{i} \leq q_{\tau}^{(1)}}-\tau\right)\right]^{2}\right]
$$

For the term

$$
D I\left(\theta^{*}\right)^{-1} \sqrt{N} \frac{1}{N} \sum_{i=1}^{n} U_{2}\left(\theta^{*}\right)
$$

the mean is 0 and the variance is $D I\left(\theta^{*}\right)^{-1} D^{\top}$.
For the covariance,

$$
\begin{align*}
& \operatorname{COV}\left(\frac{\mathbb{1}_{A_{i}=1}}{P\left(A_{i}=1 \mid L_{i}\right)}\left(\mathbb{1}_{Y_{i} \leq q_{\tau}^{(1)}+\frac{\delta}{\sqrt{N}}}-\tau\right), U_{2}\right) \\
& \quad=E\left(\frac{\mathbb{1}_{A_{i}=1}}{P\left(A_{i}=1 \mid L_{i}\right)}\left(\mathbb{1}_{Y_{i} \leq q_{\tau}^{(1)}+\frac{\delta}{\sqrt{N}}}-\tau\right) \cdot U_{2}\right) . \tag{A14}
\end{align*}
$$

Similar to the reasoning for the variance in the proof of Theorem3, the integrand is bounded by an integrable function. In addition, as $N \rightarrow \infty$,

$$
\frac{\mathbb{1}_{A_{i}=1}}{P\left(A_{i}=1 \mid L_{i}\right)}\left(\mathbb{1}_{Y_{i} \leq q_{\tau}^{(1)}+\frac{\delta}{\sqrt{N}}}-\tau\right) \cdot U_{2} \xrightarrow{\text { a.s. }} \frac{\mathbb{1}_{A_{i}=1}}{P\left(A_{i}=1 \mid L_{i}\right)}\left(\mathbb{1}_{Y_{i} \leq q_{\tau}^{(1)}}-\tau\right) \cdot U_{2} .
$$

Therefore, Lebesgue's Dominated Convergence Theorem Athreya and Lahiri, 2006 implies that

$$
\begin{aligned}
& E\left(\frac{\mathbb{1}_{A_{i}=1}}{P\left(A_{i}=1 \mid L_{i}\right)}\left(\mathbb{1}_{Y_{i} \leq q_{\tau}^{(1)}+\frac{\delta}{\sqrt{N}}}-\tau\right) \cdot U_{2}\right) \\
& \quad \rightarrow E\left(\frac{\mathbb{1}_{A_{i}=1}}{P\left(A_{i}=1 \mid L_{i}\right)}\left(\mathbb{1}_{Y_{i} \leq q_{\tau}^{(1)}}-\tau\right) \cdot U_{2}\right)=-D .
\end{aligned}
$$

Now, to apply the Triangular Central Limit Theorem to equation (A13), we subtract $\delta f_{Y^{(1)}}\left(q_{\tau}^{(1)}\right)$ on both sides of the inequality to obtain

$$
\begin{aligned}
& P\left(\sqrt{N}\left(\hat{q}_{\tau}^{(1)}-q_{\tau}^{(1)}\right)>\delta\right) \\
& =P\left(\sqrt{N} \frac{1}{N} \sum_{i=1}^{N} \frac{\mathbb{1}_{A_{i}=1}}{p_{\theta^{*}}\left(A_{i}=1 \mid L_{i}\right)}\left(\mathbb{1}_{Y_{i} \leq q_{\tau}^{(1)}+\frac{\delta}{\sqrt{N}}}-\tau\right)-\delta f_{Y^{(1)}}\left(q_{\tau}^{(1)}\right)\right. \\
& \left.\quad+D I\left(\theta^{*}\right)^{-1} \sqrt{N} \frac{1}{N} \sum_{i=1}^{n} U_{2}\left(\theta^{*}\right)+o_{P}(1)<-\delta f_{Y^{(1)}}\left(q_{\tau}^{(1)}\right)\right)
\end{aligned}
$$

Applying the Triangle Central Limit Theorem leads to

$$
P\left(\sqrt{N}\left(\hat{q}_{\tau}^{(1)}-q_{\tau}^{(1)}\right)>\delta\right) \rightarrow \Phi\left(-\frac{\delta f_{Y^{(1)}}\left(q_{\tau}^{(1)}\right)}{\sqrt{V}}\right)
$$

where $\Phi(\cdot)$ is the Cumulative Distribution Function of the standard normal distribution and

$$
\begin{align*}
V & =\tilde{V}-2 D I\left(\theta^{*}\right)^{-1} D^{\top}+D I\left(\theta^{*}\right)^{-1} D^{\top} \\
& =\tilde{V}-D I\left(\theta^{*}\right)^{-1} D^{\top} \tag{A15}
\end{align*}
$$

This implies that

$$
P\left(\sqrt{N}\left(\hat{q}_{\tau}^{(1)}-q_{\tau}^{(1)}\right) \leq \delta\right) \rightarrow \Phi\left(\frac{\delta f_{Y^{(1)}}\left(q_{\tau}^{(1)}\right)}{\sqrt{V}}\right)
$$

We conclude that

$$
\sqrt{N}\left(\hat{q}_{\tau}^{(1)}-q_{\tau}^{(1)}\right) \rightarrow N\left(0, \frac{V}{f_{Y^{(1)}}^{2}\left(q_{\tau}^{(1)}\right)}\right)
$$

Notice that since $D I\left(\theta^{*}\right)^{-1} D^{\top}$ is positive semi-definite, estimating the nuisance parameter $\theta$ leads to a variance of $\hat{q}_{\tau}^{(1)}$ that is at most the variance $V$ one would obtain by using the known $\theta^{*}$ (Theorem 3). This is also seen for IPTW to estimate the mean Robins et al., 1994.

## B Additional simulation results

## B. 1 Figure for simulation scenario of a time-varying setting



Figure B1: Simulation scenario of a time-varying setting with observational data

## B. 2 True causal quantiles in the point treatment setting

For the point-treatment setting, to derive the true causal quantile, we assume that $A$ is randomized so covariate $L$ is no longer a confounder for $A$. We then derive the
distribution of the ranked composite outcome in the simulated setting mathematically. The distribution of the clinical outcome in survivors is a mixture of normal distribution, while the distribution for those who die, after we assign them a value, is a point-mass.

In the point-treatment setting, for the distribution of the composite outcome under treatment $a=0$, we have

$$
\begin{aligned}
& F_{Y^{(0)}}(y)=\sum_{l \in(0,1)} P(L=l) \sum_{d \in(0,1)} P\left(D^{(0)}=d \mid L=l\right) \cdot F_{Y^{(0)} \mid D^{(0)}=d, L=l}(y) \\
= & P(L=0) \cdot P\left(D^{(0)}=1 \mid L=0\right) \cdot F_{Y^{(0)} \mid D^{(0)}=1, L=0}(y) \\
& +P(L=1) \cdot P\left(D^{(0)}=1 \mid L=1\right) \cdot F_{Y^{(0)} \mid D^{(0)}=1, L=1}(y) \\
& +P(L=0) \cdot P\left(D^{(0)}=0 \mid L=0\right) \cdot F_{Y^{(0)} \mid D^{(0)}=0, L=0}(y) \\
& +P(L=1) \cdot P\left(D^{(0)}=0 \mid L=1\right) \cdot F_{Y^{(0)} \mid D^{(0)}=0, L=1}(y) \\
= & 0.4 \cdot 0.25 \cdot 1+0.6 \cdot 0.35 \cdot 1+0.4 \cdot 0.75 F_{Y^{(0)} \mid D^{(0)}=0, L=0}+0.6 \cdot 0.65 F_{Y^{(0)} \mid D^{(0)}=0, L=1} \\
= & 0.31+0.3 F_{Y^{(0)} \mid D^{(0)}=0, L=0}+0.39 F_{Y^{(0)} \mid D^{(0)}=0, L=1},
\end{aligned}
$$

where $F_{Y^{(0)} \mid D^{(0)}=0, L=0}$ and $F_{Y^{(0)} \mid D^{(0)}=0, L=1}$ are the CDFs of normal distribution for those alive under $a=0$ :

$$
\begin{aligned}
& F_{Y^{(0)} \mid D^{(0)}=0, L=0} \sim N(0,1) \\
& F_{Y^{(0)} \mid D^{(0)}=0, L=1} \sim N(3,1) .
\end{aligned}
$$

Similarly, we derive the distribution of the composite outcome under treatment $a=1$ :

$$
F_{Y^{(1)}}(y)=0.122+0.368 F_{Y^{(1)} \mid D^{(1)}=0, L=0}+0.51 F_{Y^{(1)} \mid D^{(1)}=0, L=1} .
$$

By the definition of quantiles, solving the following linear equations for $y$ will lead to the true survival-incorporated medians $q_{0.5}^{(0)}$ and $q_{0.5}^{(1)}$

$$
\binom{F_{Y^{(0)}}(y)=0.5}{F_{Y^{(1)}}(y)=0.5}
$$

Deriving the median in the survivors is similar. The difference is that now the CDF of interests is conditional on $D=0$ :

$$
\begin{aligned}
& F_{Y^{(0)} \mid D^{(0)}=0}(y)=\frac{30}{69} F_{Y^{(0)} \mid D^{(0)}=0, L=0}+\frac{39}{69} F_{Y^{(0)} \mid D^{(0)}=0, L=1} \\
& F_{Y^{(1)} \mid D^{(1)}=0}(y)=\frac{368}{878} F_{Y^{(1)} \mid D^{(1)}=0, L=0}+\frac{510}{878} F_{Y^{(1)} \mid D^{(1)}=0, L=1} .
\end{aligned}
$$

Setting those two CDFs equal 0.5 and solving those two equations will lead to true causal parameters of median in the survivors.

## B. 3 True causal quantiles in the time-varying setting

For the time-varying setting, similar to the point-treatment setting, we derive the distribution of the ranked composite outcome, and we solve the equations of those distribution functions to get the true causal quantile.

We show how to derive the true survival-incorporated median $q_{0.5}^{(0,0)}$ under treatment regimen $(0,0)$. The survival-incorporated median under treatment regimen $(1,1) q_{0.5}^{(1,1)}$ and the median in the survivors follow a similar derivation. The CDF of the potential composite outcome $Y^{(0,0)}$ under $(0,0)$ is

$$
\begin{aligned}
& F_{Y^{(0,0)}}(y)=\sum_{l_{0} \in(0,1)} P\left(L_{0}=l_{0}\right) P\left(D_{1}^{(0)}=0 \mid L_{0}=l_{0}\right) F_{Y^{(0)} \mid D_{1}^{(0)}=1, L_{0}=l_{0}}(y) \\
& \quad+\sum_{l_{0} \in(0,1)} P\left(L_{0}=l_{0}\right) P\left(D_{1}^{(0)}=0 \mid L_{0}=l_{0}\right) \\
& \times \sum_{l_{1} \in(0,1)} P\left(L_{1}^{(0)}=l_{1} \mid L_{0}=l_{0}\right) P\left(D_{2}^{(0)}=1 \mid L_{1}=l_{1}\right) F_{Y^{(0)} \mid D_{2}^{(0)}=1, L_{0}=l_{0}, L_{1}=l_{1}}(y) \\
& +\sum_{L_{0} \in(0,1)} P\left(L_{0}\right) P\left(D_{1}^{(0)}=0 \mid L_{0}\right) \sum_{L_{1} \in(0,1)} P\left(L_{1}^{(0)} \mid L_{0}\right) P\left(D_{2}^{(0)}=0 \mid L_{0}\right) F_{Y^{(0)} \mid D_{2}^{(0)}=0, L_{0}, L_{1}}(y) .
\end{aligned}
$$

Plug in the conditional probabilities from our simulated setting, we get

$$
\begin{aligned}
F_{Y^{(0,0)}}(y)= & 0.185 F_{Y^{(0)} \mid D_{1}^{(0)}=1, L_{0}, L_{1}}(y)+0.073 F_{Y^{(0,0)} \mid D_{2}^{(0,0)}=1, L_{0}, L_{1}}(y) \\
& +0.237 F_{Y^{(0,0)} \mid D_{2}^{(0,0)}=0, L_{0}=0, L_{1}=0}(y)+0.084 F_{Y^{(0,0)} \mid D_{2}^{(0,0)}=0, L_{0}=0, L_{1}=1}(y) \\
& +0.117 F_{Y^{(0,0)} \mid D_{2}^{(0,0)}=0, L_{0}=1, L_{1}=0}(y)+0.304 F_{Y^{(0,0)} \mid D_{2}^{(0,0)}=0, L_{0}=1, L_{1}=1}(y),
\end{aligned}
$$

All CDFs follow normal distributions of survivors.
By the definition of quantiles, solving the equation

$$
F_{Y^{(0,0)}}(y)=0.5
$$

leads to a true median of the composite outcome $Y$ under treatment regimen $(0,0)$, which is our true survival-incorporated median $q_{0.5}^{(0,0)}$.

## B. 4 Simulation results using true propensity score

|  |  | Truth | Weighted (IPTW) estimation |  | Unweighted estimation |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: |
|  |  |  | rMSE | Bias | rMSE | Bias |
| $a=0$ | $\mathrm{N}=500$ | 0.328 | 0.307 | 0.007 | 0.464 | -0.429 |
|  | $\mathrm{N}=1500$ |  | 0.217 | 0.004 | 0.444 | -0.426 |
|  | $\mathrm{N}=5000$ |  | 0.096 | 0.001 | 0.428 | -0.424 |
| $a=1$ | $\mathrm{N}=500$ | 0.606 | 0.273 | -0.004 | 0.818 | 0.806 |
|  | $\mathrm{N}=1500$ |  | 0.193 | 0.001 | 0.814 | 0.808 |
|  | $\mathrm{N}=5000$ |  | 0.093 | 0.002 | 0.813 | 0.802 |

Table B1: Simulation results of the estimation of the survival-incorporated median with the true propensity score in a point-treatment setting. Truth: true population quantile. IPTW: Inverse Probability of Treatment Weighting. rMSE: Root Mean Squared Error.


Table B2: Simulation results of the estim5ttion of the survival-incorporated median in a time-varying setting with the true propensity score. Truth: true population quantile.

We show the simulation results of the estimation of the survival-incorproated median with true propensity score. Table B1 uses $p\left(A_{i}=a \mid L_{i}\right)$, instead of the estimated $\hat{p}\left(A_{i}=\right.$ $\left.a \mid L_{i}\right)$, to compute the IPTW:

$$
w_{i}=\frac{\mathbb{1}_{A_{i}=a}}{p\left(A_{i}=a \mid L_{i}\right)} .
$$

These weights $w_{i}$ are then plugged into our quantile estimator (equation (11) to estimate the survival-incorporated median.

Appendix Table B1 and Table B2 show the results of the estimation of the survivalincorporated median with the true propensity score in the point-treatment setting and the time-varying setting. The survival-incorporated median estimated based on the estimated propensity score has smaller rMSE (Table 5 and 6) than the survival-incorporated median based on the true propensity score. Hence, the estimator using the estimated propensity score is more efficient than using the true propensity score (Lok, 2021).

## C Additional details in application

We calculated the adapted Framingham Risk Score D'Agostino Sr et al. 2008 based on the following formula:

$$
\begin{aligned}
& \text { Risk factor }=3.06117 \ln (\text { Age })+1.12370 \ln (\text { Total cholesterol }) \\
& \qquad-0.93263 \ln (H D L \text { cholesterol })+\mathbb{1}_{\text {Cigarette smoker }}+\mathbb{1}_{\text {Diabetes }}-23.9802 \\
& \text { Adapted Framingham Risk Score }=100 \cdot\left(1-0.88936^{\exp (\text { risk factor })}\right) \text {, }
\end{aligned}
$$

Comparing to the original Framingham Risk Score, we excluded the term

$$
\ln (\text { Systolic blood pressure }) \times \mathbb{1}_{\text {On blood pressure medication }}
$$

due to the lack of information in LLFS.
We used the R function "weighted_quantile" from the R package "MetricsWeighted" to estimate the survival-incorporated median QoL score under each treatment. We used the R function "boot" from the R package "boot" to construct bootstrap CI for the estimated survival-incorporated median.

## Reference

Krishna B Athreya and Soumendra N Lahiri. Measure theory and probability theory, volume 19. Springer, 2006.

Ralph B D'Agostino Sr, Ramachandran S Vasan, Michael J Pencina, Philip A Wolf, Mark Cobain, Joseph M Massaro, and William B Kannel. General cardiovascular risk profile for use in primary care: the framingham heart study. Circulation, 117(6):743-753, 2008.

James M Robins, Andrea Rotnitzky, and Lue Ping Zhao. Estimation of regression coefficients when some regressors are not always observed. Journal of the American statistical Association, 89(427):846-866, 1994.

Aad W Van der Vaart. Asymptotic statistics, volume 3. Cambridge university press, 2000.


[^0]:    *This work was sponsored by NSF grant DMS 1854934 to Judith J. Lok and NIA grant U19AG063893 to all Long Life Family Study investigators. This paper constitutes the second part of Qingyan Xiang's PhD dissertation. The authors would like to thank his dissertation committee members, Ronald J. Bosch, Sara Lodi, and Yorghos Tripodis, for their invaluable input.

